リウマチ病セミナーVIII

書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

9,020 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

4,510 円(税込)

購入する

商品紹介

とりあげたいずれの領域でも、従来跫音の鈍かった臨床的研究の目覚しい進展があり、数年前と比べ格段の相異に驚かされる。しかしながら、疾患の改善や予防は、ことにリウマチ病では老化現象と相俟って、社会的環境やライフスタイルの面からの影響が大きく長期にわたるfollow up、確実なoutcomeの評価が求められているので、この点に特に留意して判断することを忘れてはならない。

目次

  • リウマチ病セミナーVIII

    ―　目　次　―

    炎症リウマチ

    骨関節、脊椎、神経

    燐・カルシウム代謝

    検査法

    生物学的反応

    治療と副作用

    手術

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

炎症リウマチ

P.7 掲載の参考文献
1) 秋山真志, 松尾幸朗:日本乾癬学会登録症例の集計-2001年-. 第16回日本乾癬学会記録集, pp151-159, 2001.
 
2) 谷垣武彦, 倉知貴志郎, 田崎典子ら:乾癬性関節炎の臨床研究. 日本職業・災害医学会誌 (投稿中).
 
3) Moll JMH, Wright V:Psoriatic arthritis. Semin Arthritis Rheum 3:5578, 1973.
 
4) Ruzicka T:Psoriatic arthritis New types, New treatment. Arch Dermatol 132:215219, 1996.
 
5) Muto M, Nagai K, Mogami S, et al:HLA antigens in Japanese patients with psoriatic arthritis. Tissue Antigens 45:362-364, 1995.
PubMed
6) 橋本公二, 村田紀和:乾癬性関節炎. リウマチ病セミナーVI (七川歡次監修), pp9-14, 大阪, 永井書店, 1995.
 
7) 塩原哲夫:乾癬の主観的病態論. 日本皮膚科学雑誌103:1636-1641, 1993.
 
8) Jones G, Grotty M, Brooks P and the psoriatic arthritis metaanalysis study group:Psoriatic arthritis:a quentitative overview of therapeutic options. Br. J Rheumatol 36:95-99, 1997.
 
9) Mazzanti G, Coloni L, De sabbata G, et al:Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Dermatol Venereal 74 suppl 186:116-117, 1994.
 
10) 佐伯行彦:抗サイトカイン療法, リウマチ病セミナーXIII (七川歡次監修), pp174-178, 大阪, 永井書店, 2002.
 
11) Ellis CN, Variani J, Fisher GJ, et al:Troglitazone improves psoriasis and normalizers model of proliferative skin desease. Arch Dermatol 136:609-616, 2000.
 
12) Okazaki R, Toriumi M, Fukumoto S, et al:Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 140:5060-5065, 1999.
PubMed
P.25 掲載の参考文献
1) 森 正樹, 水島 裕:ベーチェット病. 膠原病と近縁疾患, (織田敏次他編), pp257-269, 大阪, 永井書店, 1979.
 
2) ベーチェット病診断の手引き. 厚生省特定疾患ベーチェット病調査研究斑, 昭和61年度研究業績, pp 11-15, 1987.
 
3) International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet 335:1078-1080, 1990.
 
4) Kaklamani VG, Variopoulos G, Kaklamanis PG:Behcet's disease. Semin Arthritis Rheum 27:197-217, 1998.
 
5) Mizuki N, et al:Pathogenic gene responsible for the predisposition of Behcet's disease. Int Rev Immunol 14:33-48, 1997.
PubMed
6) Mizuki N, Ota M, Katsuyama Y, et al:Association analysis between the MIC-A and HLA-B alleles in Japanese patients with Behcet's disease. Arthritis Rheum 42:1961-1966, 1999.
 
7) 田中孝男, 鈴木 潤, 山川直之ら:網膜および溶連菌熱ショック蛋白質60の分子生物学的検討. 日眼会誌 104:328-333, 2000.
 
8) Ehrlich GE:Vasculitis in Behcet's disease. Int Rev Immunol 14:81-88, 1997.
PubMed
9) Haznedaroglu S, Karaaslan Y, Buyukasik Y, et al:Selectin adhesion molecules in Behcet's disease. Ann Rheum Dis 59:61-63, 2000.
 
10) Sakane T, Takeno M, Suzuki N, et al:Behcet's disease. N Engl J Med 341:1284-1291, 1999.
PubMed
11) Hirohata S, Hashimoto T:Abnormal T cell responses to bacterial superantigens in Behcet's disease. Clin Exp Immunol 112:317-324, 1998.
PubMed
12) Kaklamani VG, Kaklamanis PG:Treatment of Behcet's disease-An update. Semin Arthritis Rheum 30:299-312, 2001.
PubMed
13) Benamour S, Zeroual B, Alaoui FZ:Joint manifestations in Behcet's disease. Rev Rhum [Engl Ed] 65:299-307, 199825
 
15) Ertenli I, Kiraz S, Calguneri M, et al:Synovial fluid cytokine levels in Behgetis disease. Clin Exp Rheumatol 19 (5 Suppl 24):S37-41, 2001.
 
16) Akpolat T, Akkoyunlu M, Akpolat I, et al:Renal Behcet's disease:acumulative analysis. Semin Arthritis Rheum 31:317-337, 2002.
 
17) Ehrlich GE:Vasculitis in Behcet's disease. Int Rev Immunol 14:81-88, 1997.
PubMed
18) Siva A, Kantarci OH, Saip S, et al:Behcet's disease:diagnostic and prognostic aspects of neurological involvement. J Neurol 248:95-103, 2001.
PubMed
19) Hirohata S, Suda H, Hashimoto T:Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behcet's disease. J Neurol Sci 159:181-185, 1998.
PubMed
20) Akman-Demir G, Serdaroglu P, Tasgi B et al:Clinical patterns of neurological involvement in Behcet's disease:evaluation of 200 patients. Brain 122:2171-2181, 1999.
 
21) Inaba G:Behcet's disease. In:Handbook of clinical neurology (ed by McKendall RR), Viral disease, Vol 12, pp593-610, Amsterdam, Elsevier Science Pub, 1989.
 
22) Evereklioglu C, Er H, Turkoz Y, et al:Serum Ievels of TNF-alpha, sIL-2R, IL6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease. Mediators Inflamm 11:87-93, 2002.
 
23) 太田晃一, 小原克之, 佐藤秀樹ら:神経ベーチェット病の中枢神経病変のMRI拡散強調画像における特徴. 臨床神経 40:398-401, 2000.
 
24) Vignola S, Nobili F, Picco P, et al:Brain perfusion SPECT in juvenile neuro-Behcet's sdisease. J Nucl Med 42:1151-1157, 2001.
 
25) Yurdakul S, Mat C, Tuzun Y, et al:A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 44:2686-2692, 2001.
PubMed
26) Hamuryudan V, Mat C, Saip S, et al:Thalidomido in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann lntern Med 128:443-450, 1998.
PubMed
27) Kotter I, Durk H, Saal J, et al:Therapy of Behcet's disease. Ger J Ophthalmol 5:92-97, 1996.
PubMed
28) Toker E, Kazokoglu H, Acar N:High dose intravenous steroid therapy for severe posterior segment uveitis in Behcet's disease. Br J Ophthalmol 86:521-523, 2002.
 
29) 増田寛治郎:厚生省特定疾患ベーチェット病調査研究班, 平成4年度業績集, p245, 1993.
 
30) Wechsler B, Bodaghi B, Fardeau C, et al:Ethcacy of interferon alfa-2a in severe and refractory uveitis associated with Behcet's disease. Ocular Immunol Inflam 8:293-301, 2000.
 
31) Demiroglu H, Ozcebe OI, Barista I, et al:Interferon alfa-2b, colchicine, and benzathine penicnlin versus colchicine and benzathin penicillin in Behcet's disease:a randomised trial. Lancet 355:605-609, 2000.
PubMed
32) Alpsoy E, Durusoy C, Yilmaz E, et al:Interferon alfa-2a in the treatment of Behcet's disease:a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467-471, 2002.
PubMed
33) Sfikakis PP, Theodossiadis PG, Katsiari CG, et al:Eiifect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358:295-296, 2001.
PubMed
34) Munoz-Fernandez S, Hidalgo V, Fernandez-Melon J, et al:Effect of infliximab on threatening panuveitis in Behcet's disease. Lancet 358:1644, 2001.
 
35) Rozenbaum M, Rosner I, Portnoy E:Remission of Behcet's syndrome with TNFalpha blocking treatment. Ann Rheum Dis 61:283-284, 2002.
PubMed
36) Travis SP, Czajkowski M, McGovern DP, et al:Treatment of intestinal Behcet's syndrome with chimeric tumour necrosis factor alpha antibody. Gut 49:725-728, 2001.
 
37) Akman-Demir G, Baykan-Kurt B, Serdaroglu P, et al:Seven-year follow-up of neurologic involvement in Behcet's syndrome. Arch Neurol 53:691-694, 1996.
PubMed
38) 須田洋子:進行性神経ベーチェット病に対するメトトレキサート少量パルス療法. 日本臨床免疫学会会誌 22:13-22, 1999.
 
P.31 掲載の参考文献
1) Giedion A, Holthusen W, Masel LF, et al:Subacute and chronic symmetrical osteomyelitis. Ann Radiol 15:329-342, 1972.
PubMed
2) Bjorksten B, Bonquist L:Histopathological aspects of chronic recurrent multifocal osteomyelitis. J Bone Joint Surg 62B:376-380, 1980.
 
3) 藤田郁夫, 山口高史, 渡辺康司ら:再発性多発性慢性骨髄炎の一例. 整形外科45:69-72, 1994.
 
4) 牧 宏和, 永井素大, 上野博嗣ら:再発性多発性慢性骨髄炎と思われた症例の治療経験. 日本骨・関節研究会雑誌14:47-51, 2000.
 
5) Laxer RM, Shore AD, Manson D, et al:Chronic recurrent multifocal osteomyelitis and psoriasis:a report of a new association and review of related disorders. Semin Arthritis Rheum 17:260-270, 1988.
PubMed
6) Job-Deslandre C, Krebs S, Kahan A:Chronic recurrent multifocal osteomyelitis:five-year outcomes in 14 pediatric cases. Joint Bone Spine 68:245-251, 2001.
PubMed
7) Jurik AG, Egund N:MRI in chronic recurrent multifocal osteomyelitis. Skeletal Radiol 26:230-238, 1977.
 
8) Girschick HJ, Huppertz HI, Hamlsen D, et al:Chronic recurrent multifocal osteomyelitis in children:diagnostic value of histopathology and microbial testing. Hum Pathol 30:59-65, 1999.
 
9) Ishikawa-Nakayama K, Sugiyama E, Sawazaki S, et al:Chronic recurrent multifocal osteomyelitis showing marked improvement with corticosteroid treatment. J Rheumatol 27:1318-1319, 2000.
PubMed
10) Vittecoq O, Said LA, Michot C, et al:Evolution of chronic recurrent multifocal osteitis toward spondyloarthropathy over the long teml. Arthritis Rheum 43:109-119, 2000.
 
11) Robertson LP, Hickling P:Chronic recurrent multifocal osteomyelitis is a differential diagnosis of juvenile idiopathic arthritis. Ann Rheum Dis 60:829-831, 2001.
 
12) 川崎 拓:胸鎖関節の病態. リウマチ病セミナーXII (七川歡次監修), pp137-146, 大阪, 永井書店, 2001.
 
P.38 掲載の参考文献
1) 宮地良樹:膠原病-診断と治療の最新ポイント-皮膚から内臓へ-(宮地良樹, 竹原和彦編), pp 132-133, 東京, 診断と治療社, 1997.
 
2) Kulp-Shorten CL, Callen JP:Urticaria, angioedema, and rheumatologic disease. Rheum Dis North Amer 22:95-115, 1996.
 
3) McDuffie FC, Sam WM, Maldonado JE, et al:Hypocomplementemia with cutaneous vasculitis and arthritis; possible immune complex syndrome. Mayo Clin Proc 48:340-348, 1973.
 
4) Gammon WR, Clayton MD, Wheeler Jr CE:Urticarial vasculitis; report of a case and review of the literature. Arch Dermatol 115:76-80, 1979.
 
5) 山口雅英, 植木宏明:長期治療後に寛解に至った蕁麻疹様血管炎の2例. 西日皮膚60:137-141, 1998.
 
6) 久保田由美子, 桐生美麿, 中山樹一郎ら:多彩な症状を呈したHypocomplementemic Urticarial Vasculitis Syndromeの1例. 西日皮膚63:1621, 2001.
 
7) Ishikawa O, Miyachi Y, Watanabe H:Hypocomplementemic urticarial vasculitis associated with Jaccoud's syndrome. Br J Dermatol 137:804-807, 1997.
 
8) Palazzo E, Bourgeois P, Meyer O, et al:Hypocomplementemic urticarial vasculitis syndrome, Jaccoud's syndrome, valvulopathy:a new syndrome combination. J Rheumat 20:1236-1240, 1993.
 
9) Puddn P, Cianchini G, Girardelli CR, et al:Schnitzler's syndrome:a report of a new case and a review of the literature. Clin Exp Rheumatol 15:91-95, 1997.
 
10) Sanchez NP, Winkelmann RK, Schroeter AL, et al:The clinical and histopathological spectrums of urticarial vasculitis:study of forty cases. J Am Acad Dermatol 7:599-605, 1982.
 
11) Schwartz HR McDufiie FC, Black LF, et al:Hypocomplementemic urticarial vasculitis. Association with chronic obstructive pulmonary disease. Mayo Clin Proc 57:231-238, 1982.
 
12) Mehregan OR, Hall MJ, Gibson LE:Urticarial vasculitis:a histopathologic and clinical review of 72 cases. J Am Acad Dermatol 26:441-448, 1992.
 
13) Wisnieski JJ, Baer AN, Christensen J, et al:Hypocomplementemic urticarial vasculitis syndrome. Medicine 74:24-41, 1995.
PubMed
14) 根来 茂:蕁麻疹, 血管浮腫と関節炎. リウマチ病セミナーIII (七川歡次監修), pp68-76, 大阪, 永井書店, 1992.
 
15) 川名誠司, 西岡 清, 西山茂夫:好中球優位の細胞浸潤を伴う蕁麻疹様紅斑-urticarial vasculitisの位置づけ. 日皮会誌 101:951-957, 1991.
 
16) Asherson RA, D'Cruz D, Stephens CJ, et al:Urticarial vasculitis in a connective tissue disease clinic; pattern, presentations and treatment. Semin Arthritis Rheum 20:285-296, 1991.
 
17) 衛藤 光:膠原病のデルマドローム. MB Derma 18:59-64, 1998.
 
18) 古川隆代, 甲賀資秀, 小林 勝ら:慢性関節リウマチに併発した蕁麻疹様血管炎-DDSが奏効した1例-. 皮膚臨床 32:1213-1217, 1990.
 
19) Engler RJM, Squire E, Benson P:Chronic sulfasalazine therapy in the treatment of delayed pressure urticaria and angioedema. Am Allerg Asthema & Immunol 74:155-159, 1995.
 
20) Stack, PS:Methotrexate for urticarial vasculitis. Ann Allergy 72:3638, 1993.
 
21) 箕輪秀樹, 山下千賀子, 西久保敏也ら:溶連菌感染症の関与が示唆された蕁麻疹様血管炎の1男子例. 小児科診療12:2103-2108, 1996.
 
P.46 掲載の参考文献
1) Kaplan MJ, Richardson BC:Mechanisms of autoimmunity in environmentally induced connective tissue diseaes. In; Rheumatic Diseases and the Environment (Ed, Kaufman LD, Varga J), pp19-31, London, ARNOLD, 1997.
 
2) Rubin RL:Drug-induced lupus. In; Duboisﾕ Lupus Erythematosus, Fifth Edition (Ed, Wallace DJ, Hahn BH), pp871-899, Baltimore, Williams & Wilkins, 1997.
 
3) Elliot MJ, Maini RN, Feldmann M, et al:Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factora. Arthritis Rheum 36:1681-1690, 1993.
 
4) Charles PJ, Smeenk RJT, Jong Jde, et al:Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor a. Arthritis Rheum 43:2383-2390, 2000.
 
5) Moreland LW, Schiff MH, Baumgartner SW, et al:Etanercept therapy in rheumatoid arthritis. a randomized controlled trial. Ann Intern Med 130:478-486, 1999.
PubMed
6) Shakoor N, Michalska M, Harris CA, et al:Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 359:579-580, 2002.
PubMed
7) 藤井亜砂美, 有村義宏, 簑島 忍ら:プロピルチオウラシル内服中に肺出血を生じたミエロペルオキシダーゼに対する好好中球細胞質抗体(MPO-ANCA)関連血管炎の1例. リウマチ 37:788-793, 1997.
 
8) Choi HK Merkel PA, Walker AM, et al:Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis. Prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 43:405-413, 2000.
PubMed
9) Ten Holder SM, Joy MS, Falk RJ:Cutaneus and systemic manifestations of the drug-induced vasculitis. Ann Pharmacother 36:130-147, 2002.
 
10) Wechsler ME, Garpestad E, Flier SR, et al:Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 279:455457, 1998.
 
11) Wechsler ME, Finn D, Gunawardena D, et al:Churg-Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest 117:708-713, 2000.
PubMed
12) Wechsler ME, Pauwels R, Drazen JM:Leukotriene modifiers and Churg-Strauss syndrome. Adverse effect or response to corticosteroid withdrawal? Drug safety 4:241-251, 1999.
 
13) 熊谷安夫:II. 膠原病類縁疾患のトピックス 2.ヒト・adjuvant病. 日本内科学会雑誌80:63-66, 1991.
 
14) Kumagai Y, Shiokawa Y, Medsger Jr TA, et al:Clinical spectrum of connective tisuue disease after cosmetic surgery. Observation on eighteen patients and a review of the Japanese literature. Arthritis Rheum 27:1-12, 1984.
 
P.53 掲載の参考文献
1) Ball J:Enthesopathy of rheumatoid and ankylosing spondylitis. Ann Rheum Dis 30:213-223, 1971.
PubMed
2) Bywaters EGL:Pathology of the spondylarthropathies. Spondylarthropathies (Ed, Calin A), pp43-68, Orland, Grune & Stratton, 1984.
 
3) 七川歡次, 辻本正記, 小瀬引一ら:強直性脊椎炎, その早期診断, 頻度, 病因について. リウマチ病II (七川歡次編), pp188-216, 大阪, 永井書店, 1985.
 
4) 小松原良雄:強直性脊椎炎の病理像の考察. リウマチ病II (七川歡次編), pp217-245, 大阪, 永井書店, 1973.
 
5) Frangois RJ:Le rachis dans la spondylarthrite ankylosante. Bruxelles, Editions Arscia SA, 1976.
 
6) Shichikawa K, Tujimoto M, Nishioka J, et al:Histopathology of early sacroiliitis and enthesitis in ankylosing spondylitis. Advances in inflammation research (Ed, Ziff M, Cohen SB), Vol 9, pp15-24, New York, Raven Press, 1973.
 
7) Bollow M, Fischer T, ReiBhauser H, et al:Quantitative analyses of sacroiliac biopsy in spondyloarthropathies:Tcells and macrophages predominate in early and active sacroiliitis-cellularity correlates with the degree of enhancement detected by magnetic resonance imaging. Ann Rheum Dis 59:135-140, 2000.
 
8) Bywaters EGL:A case of early ankylosing spondylitis with fatal secondary amyloidosis. BMJ 2:412-416, 1968.
 
9) Pasion EG, Goodfellow JW:Pre-ankylosingspondylitis. Ann Rheum Dis 34:92-97, 1975.
 
10) Seki K Ueo T, Miki T, et al:Pustulotic arthro-osteitis associated with acetabular cartilage lesion in pustulotic arthropathy-implication of bone marrow. J Rheumat 24:981-973, 1997.
 
11) Francois RJ, Gardner DL, Degrave EJ, et al:Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis. Arthritis Rheum 43:2011-2024, 2000.
 
12) Ball J:The enthesopathy of ankylosing spondylitis. Brit J Rheumat 22 (supple):25-28, 1983.
 
13) Ahlstrom H, Feltelius N, Nyman R, et al:Magnetic resonance imaging of sacroiliac joint inflammation. Arthritis Rheum 33:1763-1769, 1990.
PubMed
14) Bollow M, Braun J, Hamm B, et al:Early sacroiliitis in patients with spondyloarthropathy:evaluation with dynamic gadolinium-enhanced MR imaging. Radiology 194:529-536, 1995.
PubMed
15) Braun J, Bollow M, Eggens U, et al:Use of dynamic magnetic resonance imaging with fast imaging in the detection of early and advanced sacroiliitis in spondylarthropathy patients. Arthritis Rheum 37:1039-1045, 1994.
PubMed
16) McGonagle D, Gibbon W, O'connor P, et al:Characteristic magnetic resonance imaging entheseal changes of knee synovitis in spondylarthropathy. Arthritis Rheum 41:694-700, 1998.
PubMed
17) Maksymowych W:Ankylosing spondylitis at the interface of bone and cartilage. J Rheumat 27:2295-2301, 2000.
 
18) McGonalgle D, Gibbon W, Emery P:Classification of inflammatory arthritis by enthesitis. Lancet 352:1137-1140, 1998.
 
19) 川崎 拓:Chronic recurrent multifocal osteitis. リウマチ病セミナーXIII (七川歡次監修), pp27-31, 大阪, 永井書店, 2002.
 
20) McGonagle D, Stockain L, Isaacs JD, et al:An enthesitis based model for the pathogenesis of SpA. Additive effects of microbial adjuvant and biomechanical factors at disease sites. J Rheumat 28:2155-2159, 2001.
 
21) McGonalgle D, Marza-Ortega H, O'connor P, et al:Histological assessment of the early enthesitis lesion in spondyloarthropathy. Ann Rheum Dis 61:534-537, 2002.
 

骨関節, 脊椎, 神経

P.62 掲載の参考文献
1) Rahnman P, Goldman D, Urowitz MB:Efficacy of antimalarial therapy in cutaneous lupus in smokers versus non-smokers. Arthritis Rheum 40:S166, 1997.
 
2) Ogawa K, Ogawa T, Saito E, et al:Factors relating the course of intestinal pneumonitis in patients with rheumatoid arthritis. Arthritis Rheum 40:S508, 1997.
 
3) Petri M:The effect of education on the clinical manifestation and morbidity of systemic lupus erythematosus. Arthritis Rheum 40:S525, 1997.
 
4) Petri M:Smoking is a risk factor for musculoskeletal, pulmonary and cardiac disease in systemic lupus erythematosus. Arthritis Rheum 40:S527, 1997.
 
5) Bognar MT, Varela NC, Jones S, et al:Smoking in African-American with rheumatoid arthritis is associated with high prevalence of subcutaneous rheumatical nodules. Arthritis Rheum 40:S745, 1997.
 
6) McAllinda T, Felsen D, Palmer J, et al:Associations of cigarette smoking and alcohol with systemic lupus erythematosus among participant in black women health study. Arthritis Rheum 40:S788, 1997.
 
7) Voskuyl AE, Zwindeman AH, Breedveld FC, et al:Smoking and the risk of vasculitis in rheumatoid arthritis. Arthritis Rheum 40:S834, 1997.
 
8) Vita AJ, Hubert H, Fries JA:Life-style risk factors and compression of life-time disability. Arthritis Rheum 40:S1091, 1997.
 
9) Wolfe F, Johnstone C:Rheumatoid factor and smoking; evidence for dose response independent of sex. Arthritis Rheum 40:S1336, 1997.
 
10) Fraellkel L, Zhang YG, Evans S, et al:Risk factors associated Raynauhls phenomonon (RP) are different in men and women. Arthritis Rheum 40:S1343, 1997.
 
11) Wolfe F, Johwton C:Smoking is associated with premature development of rheumatoid arthritis and osteoarthritis. Arthritis Rheum 40:S1684, 1997.
 
12) Massai AT, Aldog JC, Fecht T, et al:Rheumatoid factor positivity (RF+) and current smoking (CCS+) of 30+ daily are independent, long-term predictors of rheumatoid arthritis. Arthritis Rheum 40:S1687, 1997.
 
13) Lethbridge-Ceike M, Creamer P, Wilson PD, et al:Risk factors for incident knee osteoarthritis (OA) data from the Baltimore longitudinal study of aging (BLSA). Arthritis Rheum 41:S25, 1998.
 
14) Uhlig T, Kvien TK:Current smoking increases the risk of rheumatoid arthritis in men. Arthritis Rheum 41:S563, 1998.
 
15) Hutchinson D, Moots RJ:Cigarette smoking is positively associated with development of rheumatoid arthritis in patients without a family history of rheumatoid arthritis. Arthritis Rheum 42:S1054, 1999.
 
16) Hutchinson D, Shepstone L, Lynchi M, et al:Rheumatoid arthritis (RA) is strongly associated with increased cumlative exposure to cigarette smoke. Arthritis Rheum 42:S1055, 1999.
 
17) Harrison B, Silman A, Wiles N, et al:Cigarette smokers have a better disease outcome than non-smokers among patients with eartly inflammatory polyarthritis. Arthritis Rheum 42:S350, 1999.
 
18) Richards SCH, Eehardt CC, Scott DI:Current smoking status and impact on pain and disability in rheumatoid arthritis. Arthritis Rheum 42:S1064, 1999.
 
19) Anin S, Lavalley MP, Zhanz Y, et al:Is the effect of smoking on bone mineral density (BMD) in elderly men mediated through estradiol. Arthritis Rheum 42:S1918, 1999.
 
20) McAlinder T, Formica M, Palmer J, et al:Is childhood smoke exposure a risk factor for systemic lupus erythematosus? Results from the black women's health study (BWHS). Arthritis Rhetlm 43:S1025, 2000.
 
21) Formica MK, McAlencer TE, Palmer J, et al:Discoid lupus erytematosus (DLE) and smoking among African-American women. Arthritis Rheum 43:S285, 2000.
 
22) Saag KG, Cerhan J, Merlino L, et al:Cigarette smoking and risk of elderly onset rheumatoid arthritis; result from the Iowa women's health study. Arthritis Rheum 43:S167, 2000.
 
23) Yunus MB, Aldag JC, Peoria LJp:A study of association between current smoking and fibromyalgia (FM) symptoms. Arthritis Rheum 43:S1592, 2000.
 
24) Masi AT, Aldag JC, Melamet RL, et al:Heavy smoking of 30+cigarette daily (HS30+/D) significantly predicted onset of rheumatoid arthritis in both genders, and was an independent risk factor frome either rheumatoid factor positivity (RF+) or development of the disease in a first degree relative (FDR+). Arthritis Rheum 44:S313, 2001.
 
25) Fraser PA, Ding W, Treadwell LT, et al:Gene-environment interaction in systemic lupus erythematosus; GST will genotype, smoking, and hair treatments. Arthritis Rheum 44:S1177, 2001.
 
26) Harrison BT, Silman AJ, Hilder S, et al:Cigarette smoking; a risk factor for digital vascular complications in systemic sclerosis. Arthritis Rheum 44:S1654, 2001.
 
27) Palo Alto EK:Apopulation-based case-control study of rheumatoid arthritis and smoking; result from the behavioral risk factor surveillance system. Arthritis Rheum 44:S1835, 2001.
 
28) Saag KG, Cerham JR Kellure S, et al:Cigarette smoking and rheumatoid arthritis severity. Ann Rheum Dis 56:463-464, 1997.
 
29) Harrison BJ, Silman AJ:Does smoking influence disease outcome in patients with rheumatoid arthritis. J Rheumatol 27:569-570, 2000.
PubMed
30) Harrison BT, Silman AJ, Wiles NJ, et al:The association of cigarette smoking with disease outcome in patients with early inflammatory polyarthritis. Arthritis Rheum 44:323-330, 20013.
 
31) Wolfe F, Zwilich SH:The long-term outcomes of rheumatoid arthritis; a 23 year prespective, longitudinal study of total joint replacement and its predictors in 1600 patients with rheumatoid arthritis. Arthritis Rheum 41:1072-1078, 1998.
 
32) Wolfe F:The effect of smoking on clinical, laboratory, and radiographic studies in rheumatoid arthritis. J Rheumatol 27:630-637, 2000.
 
33) Nasodollir B, Jonsson T, Manbreodottir V, et al:Smoking, rheumatoid factor isotopes and severity of rheumatoid arthritis. Rheumatology 39:1202-1205, 2000.
 
34) Heliovaara M, Aho K, Kneht P, et al:Coffee consumption, rheumatoid factor, and the risk of rheumatoid arthritis. Ann Rheum Dis 59:631-635, 2000.
PubMed
35) Huchinsonn D, Shepsone L, Moots R, et al:Heavy cigarette smoking is strongly associated with rheumatoid arthritis, particularly in patients without a family history of rheumatoid arthritis. Ann Rheum Dis 60:2232-2237, 2000.
 
36) Symmons DPM, Bankhead CR, Harrison BT, et al:Blod transfusion, smoking, and obesity as risk factor for the development of rheumatoid arthritis. Results from a primary case-based incident case-control study in Norfolk, England. Arthritis Rheum 46:1955-1961, 1997.
 
37) Heliovaara M, Aho K, Aromaa A, et al:Smoking and risk of rheumatoid arthritis. J Rheumatol 20:1830-1835, 1993.
PubMed
38) Hernandez-Avila M, Liang MH, Willet C, et al:Reproduction factors, smoking, and the risk for rheumatoid arthritis. Epidemiology 1:285-291, 1990.
 
39) Masi AT, Fecht T, Aldad JC, et al:History of currently smoking cigarettes, but not years of education, corrected with Subsequent development of rheumatoid arthritis. Arthritis Rheum 39 (Suppl):S301, 1996.
 
40) Uhig T, Hagen KB, Kwien TK:Current tobacco smoking, formal education and the risk of rheumatoid arthritis. JRheumatol 36:47-54, 1999.
 
41) Tuomi T, Heliovaara M, Palosuo T, et al:Smoking, lung function, and rheumatoid arthritis. Ann Rheum Dis 49:735-756, 1990.
 
42) McDonagh JE, Walker DJ:Smoking and rheumatoid arthritis observation from a multicase family study; comment on the article by Silman, et al. Arthritis Rheum 40:594, 1997.
PubMed
43) Jonsson J, Thorsteinsson T, Valdimarsson H:Does smoking stimulate rheumatoid factor production in non-rheumatic individuals? APMIS 106:970-974, 1998.
 
44) Voigt LF, Koepsell TD, Nelson JL, et al:Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology 5:52-56, 1994.
 
45) Kneht P, Heliovaara M, Aho R, et al:Serum selenium, serum alpha-tocophenol, and the risk of rcc. Epidemiol 11:402-405, 2000.
 
46) Ghaussy NO, Sibbitt WL, Qualls CR:Cigarette smoking, alcohol consumption, and the risk of systemic lupus erythematosus; a case-control study. J Rheumatol 38:2449-2453, 2001.
 
47) Anderson JJ, Felson DT:Factors associated With osteoarthritis of the knee in the first national health nutrition survey (Hanes D. Amer J Epidemiol 128:179-184, 1988.
 
48) Felson DT, Andersson JJ, Naimark A, et al:Does smoking Protect against osteoarthritis. Arthritis Rheum 32:166-172, 1989.
 
49) Samanta A, Jones A, Regan M, et al:Is osteoarthritis in women affected by hormonal change or smoking? Brit J Rheumatol 32:366-370, 1993.
PubMed
50) Hart JJ, Spector TD:Cigarette smoking and risk of osteoarthritis in women in general population; The Chingford study. Ann Rheum Dis 52:93-96, 1993.
 
51) Vingard E, Alfredsson L, Malchan H:Life style factors and hip arthrosis; a case study of body mass index, smoking, and hormonal therapy in 503 swedish women. Acta Orthop Scand 68:216-220, 1997.
 
52) Alverns HL, Oxtaby J, Taylor HG, et al:Smoking and outcome in ankylosing spondylitis. Scand J Rheumatol 25:138-142, 1996.
 
53) Bendavid EJ, Shan J, Barrett-conna E:Factors associated with bone mineral density in middle-aged men. JBMR 11:1185-1192, 1996.
 
54) Daniell HW:Osteoporosis of the slender smoker; vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and loss of obesity. Arch Int Med 136:298-301, 1976.
 
55) Slemenda CW, Christica JC, Reed T, et al:Long-term bone loss in men:Effect of genetic and environmental factors. Ann Rheum Dis 117:286-291, 1992.
 
56) Orwall ES, Bevan L, Phipps KR:Determination of bone mineral density in old men. Osteoprosis Int 11:815-821, 2000.
 
57) Pullan RD, Rhodes J, Ch BM, et al:Transdermal nicotins for active ulcerative colitis. New Engl J Med 330:811-815, 1994.
 
58) Manthorpe R, Benoni C, Jacobsson L, et al:Low frequency of focal lip sialadenitis (focus score) in smoking patients, Can tobacco diminish the salivary gland involvement as judged by histological examination and anti-SSA/Ro and anti-SSB/La antibodies in Sjogren syndrome? Ann Rheum Dis 59:54-60, 2000.
 
59) Ginnes LC, Ryu JH, Rogol PR, et al:Natural killer cell activity in cigarette smokers and asbestos workers. AM Rew Respir Dis 31:831-943, 1985.
 
60) Khaw Kr, Tazuke S, Bamett-Connor E:Cigarette smoking and levels of adrenal androgens in postmemopausal women. New Engl J Med 318:1705-1709, 1988.
 
62) Baron JA:Beneficial effects of nicotins and cigarette smoking; the real, the possible and the spurious. Brit Med Bull 52:58-73, 1996.
 
64) Deighton C:Smoke gets in your joints? Ann Rheum Dis 36:453-454, 1997.
 
P.69 掲載の参考文献
1) 遠藤健司, 馬場久敏, 長島親男 (監訳):むち打ち損傷, 診断と治療, 東京, シュプリンガーフェアラーク 東京, 2000.
 
2) 遠藤健司, 市丸勝二, 今給黎篤弘:MRAによる頸性めまい (椎骨脳底動脈循環不全) の診断. 別冊整形外科 38:155-159, 2000.
 
3) 遠藤健司, 市丸勝二, 今給黎篤弘:Barre-Lieou症候群. MB Orthop 12:45-53, 1999.
 
4) Shimura H, Yuzawa K, Nozue M:Stroke after visit to the hairdresser. Lancet 1778:350, 1997.
 
5) 長島親男:頸性めまい. Medicina 37:6673, 1977.
 
6) 渡辺正樹ら:眩量を主訴とする椎骨脳底動脈循環不全群のMRIによる検討. Equibrium Res 32:708-712, 1992.
 
7) Endo K:Ichimaru K, lmakiire A, et al:Cervical vertigo after hair shampoo treatment at a hairdressing salon. Spine 25:632-634, 2000.
 
P.79 掲載の参考文献
1) White AA III, Panjabi MM:Clinical biomechanics of the spine (2nd ed), pp351-357, Philadelphia, JB Lippincott, 1990.
 
2) Shaffer WO, Spratt KF, Weinstein J, et al:The consistency and accuracy of roentgenograms for measuring sagittal translation in the lumbar vertebral motion segment. Spine 15:741-750, 1990.
PubMed
3) Boden SD, Wiesel SW:Lumbosacral segmental motion in normal individuals. Have we been measuring instability properly? Spine 15:571-576, 1990.
PubMed
4) Weiler PJ, King GJ, Gertzbein SD:Analysis of sagittal plane instability of the lumbar spine in vivo. Spine 15:1300-1306, 1990.
PubMed
5) 三村雅也, 守屋秀繁, 北原 宏ら:腰椎分離・すべり症, 変性すべり症における回旋不安定性について. 臨整外25:387-392, 1990.
 
6) Iguchi T, Wakami T, Kurihara A, et al:Lumbar multilevel degenerative spondylolisthesis. J Spinal Disord & Tec 15:93-99, 2002.
 
7) 真鍋道彦, 井口哲弘, 栗原章ら:腰椎変性すべり症の臨床所見の検討. 臨整外 (投稿中2002年11月出版予定) .
 
8) Katz JN, Lipson SJ, Chang LC, et al:Seven-to 10-year outcome of decompressive surgery for degenerative lumbar spinal stenosis. Spine 21:92-98, 1996.
PubMed
9) Iguchi T, Kurihara A, Nakayama J, et al:Minimum 10-year outcome of decompressive laminectomy for degenerative lumbar spinal stenosis. Spine 25:1754-1759, 2000.
PubMed
10) Nachemson A:The role of spine fusion. Spine 6:306-307, 1981.
 
11) Dupuis PR, Yong-Hing K, Cassidy JD, et al:Radiologic diagnosis of degenerative lumbar spinal instability. Spine 10:262-276, 1985.
PubMed
12) 川上 守, 玉置哲也, 吉田宗人ら:腰椎変性すべり症における単純X線像を用いた不安定性評価法の信頼性. 臨整外33:615620, 1998.
 
13) Nizard RS, Wybier M, Laredo J-D:Radiologic assessment of lumbar intervertebral instability and degenerative spondylolisthesis. Radiol Clin North Am 39:5571, 2001.
 
14) 原田雅仁, 鐙 邦芳, 伊藤 学ら:シネラジオグラフィーによる不安定腰椎の連続的動態解析. 口臨バイオメカ誌17:139-142, 1996.
 
15) Okawa A, Shinomiya K, Komori H, et al:Dynamic motion study of the whole lumbar spine by videofluoroscopy. Spine 23:1743-1749, 1998.
PubMed
16) Lang P, Chafetz N, Genant HK, et al:Lumbar spinal fusion. Assessment of functional stability with magnetic resonance imaging. Spine 15:581-588, 1990.
PubMed
17) Friberg O:Lumbar instability. A dynamic approach by traction-compression radiography. Spine 12:119-129, 1987.
PubMed
18) 増本眞悟, 今井 健, 角南義文:腰椎変性すべり症の予後に影響する因子の検討. 日本腰痛会誌6:21-27, 2000.
 
19) 松永俊二, 酒匂崇, 森園良幸ら:腰椎変性すべり症の自然経過. 臨整外 25:425-432, 1990.
 
20) Kirkaldy-Willis WH, Farfan HF:Instability of the lumbar spine. Clin Orthop 165:110-123, 1982.
PubMed
21) 里見和彦, 平林 洌, 藤村祥一ら:腰椎変性すべり症の症状発現機序と治療法の選択. 臨整外 25:399-406, 1990.
 
P.87 掲載の参考文献
1) 平山恵造, 豊倉康夫, 椿忠雄:筋萎縮症の新特異型の存在について; 若年に発症し一側前腕より末梢に限局する進行の遅い特殊な筋萎縮症. 精神神経誌 61:2190-2197, 1959.
 
2) 平山恵造, Tomonaga M, Kitano Kら:若年性一側上肢筋萎縮症の初剖検例. 神経内科 22:8588, 1985.
 
3) Hirayama K, Tomonaga M, Kitano K, et al:Focal cervical poliopathy causing juvenile muscular atrophy of distal upper extremity; a pathological study. J Neurol Neurosurg Psychiatry 50:285-290, 1987.
PubMed
4) 向井栄一郎, 祖父江逸郎, 武藤多津郎ら:若年性上肢遠位部髄節性筋萎縮症のレ線学的異常所見. 臨床神経25:620-626, 1985
 
5) 菊地誠志, 田代邦雄, 北川まゆみら:若年性限局性手・前腕筋萎縮症 (平山病) の発生機序に関する一考 察; Tight dural canal in flexionを伴うflexion myelopathy. 臨床神経 27:412-419, 1987.
 
6) 得丸幸夫, 平山恵造:若年性一側上肢筋萎縮症における下部頸髄硬膜後壁の前方移動について. 臨床神経 29:1237-1243, 1989.
 
7) 得丸幸夫, 平山恵造:若年性一側上肢筋萎縮症 (平山病) の頸椎カラー治療成績. 臨床神経 32:1102-1106, 1992.
 
8) 若年性一側上肢筋萎縮症 (平山病) 全国調査研究グループ (代表平山恵造) . 若年性一側上肢筋萎縮症 (平山病) 全国調査. 北海道大学医学部神経内科内「若年性一側上肢筋萎縮症 (平山病) 全国調査研究グループ事務局」, pp 1-36, 2000.
 
9) Pilgaard S:Unilateral juvenile muscular atrophy of upper limbs. Acta Orthop Scand 39:327-331, 1968.
PubMed
10) Adomato BT, Engel WK, Kucera J, et al:Benign focal amyotrophy. Neurology 28:399, 1978.
 
11) Singh N, Sachdev KK, Susheela AK:Juvenile muscular atrophy localized to arms. Arch Neurol 37:297-299, 1980.
PubMed
12) Tan CT:Juvenile muscular atrophy of distal upper extremities. J Neurol Neurosurg Psychiatry 48:285-286, 1985.
PubMed
13) Virmani V, Mohan PK:Non-familial, spinal segmental muscular atrophy in juvenile and young subjects. Acta Neurol Scand 72:336340, 1985.
 
14) Peiris JB, Seneviratne KN, Wickremashighe HR, et al:Non-familial jevenile distal spinal muscular atrophy of upper extremity. J Neurol Neurosurg Psychiatry 52:314-319, 1989.
 
15) Chan W, Kay R, Schwartz MS:Juvenile distal spinal muscular atrophy of upper extremities in Chinese males; a single fiber electromyographic study of arms and legs. J Neurol Neurosurg Psychiatry 54:165-166, 1991.
 
16) Kao KP, Wu ZA, Chem CM:Juvenile lower cervical spinal muscular atrophy in Taiwan; report of 27 Chinese cases. Neuroepidemiol 12:331-335, 1993.
 
17) Mirsa UK, Kalita J:Central motor conduction in Hirayama disease. Electroenceph Clin Neurophysiol 97:73-76, 1995.
 
18) Schroder R, Keller E, Flacke S, et al:MRI findings in Hirayama's disease; flexion-induced cervical myelopathy or intrinsic motor neuron disease? J Neurol 246:1069-1074, 1999.
PubMed
19) Robberecht W, Aguirre T, Van Den Bosch L, et al:Familial juvenile focal amyotrophy of the upper extremity (Hirayama disease). Arch Neurol 54:46-50, 1997.
PubMed
20) Nascimento OJ, Freitas MR:Non-progressive juvenile spinal muscular atrophy of the distal upper limb (Hirayama's disease); a clinical variant of the benign monomelic amyotrophy. Arq Neuropsiquiatr 58:814-819, 2000.
 
21) Drozdowski W, Baniukiewicz E, Lewonowska M:Juvenile monomelic amyotrophy; Hirayama disease. Neurol Neurochir Pol 32:943-950, 1998.
PubMed
22) Chen CJ, Chen CM, Wu CL, et al:Hirayama disease; MR diagnosis. AJNRAm J Neuroradiol 19:365-368, 1998.
 
P.96 掲載の参考文献
1) 内尾祐司, 越智光夫:離断性骨軟骨炎. 整・災外 3:1207-1016, 2000.
 
2) 松末吉隆, 中川泰彰, 中村孝志:膝離断性骨軟骨炎. 整・災外 43:1269-1278, 2000.
 
3) Aichroth P:Osteochondritis dissecans. Surgery of the knee, 2nd ed (ed, Insall LN), pp217-239, New York, Churchill Livingstone, 1993.
 
4) Aichroth P:Osteochondritis, dissecans of the knee. A clinical survey. J Bone Joint surg 53-B:440-447, 1971.
 
5) 久保俊一, 堀井基行:骨髄浮腫. リウマチ病セミナーIX (七川歡次監修), pp94-103, 大阪, 永井書店, 1998.
 
6) Resnick D, Georgen TG:Traumatic diseases or physical injury. Concepts and terminology. Osteochondritis dissecans. Diagnosis of bone and joint disorders, 4th ed, pp2689-2708, Philadelphia, Saunders, 2002.
 
7) 広畑和志:いわゆる膝内障の病理組織像とその臨床的意義. 日整会誌 50:53-65, 1976.
Medical*Online
8) Takahara M, Ogino T, Takagi M, et al:Natural progression of osteochondritis dissecans of the humeral capitellum; Initial observations. Radiology 216:207-212, 2000.
PubMed
9) 飛田正敏, 安達伸生, 河崎賢三ら:肘関節離断性骨軟骨炎におけるMRIの有用性. 整スポ会誌 20:283-287, 2000.
 
10) 西林保朗:靱帯のhyperlaxityと過度運動性症候群. リウマチ病セミナーX (七川歡次監修), pp114-132, 大阪, 永井書店, 1999.
 
11) 西林保朗:リウマチ性疾患の四肢痛. リウマチ科27:151-161, 2002.
 

燐・カルシウム代謝

P.104 掲載の参考文献
1) Yamamoto M, Kawanobe Y, Takahashi H, et al:Vitamin D deficiency and calcium transport in the rat. J Clin Invest 74:507-513, 1984.
 
2) Yamamoto M, Takuwa Y, Masuko S, et al:Effect of endogenous and exogeneous parathyroid hormone on tubular reabsorption of calcium in pseudohypoparathyroidism. J Clin Endocrinol Metab 66:618-625, 1988.
PubMed
3) Shimizu T, Yoshitomi K, Nakamura M, et al:Effects of PTH, calcitonin and cAMP on calcium transport in rabbit distal nephron segments. Am J Physiol 28:F408-414, 1990.
PubMed
4) Shimizu T, Yoshitomi K, Nakamura M, et al:Effects of parathyroid hormone on the connecting tubule from the rabbit kidney; biphasic response of transluminal voltage. Ptluegers Arch 416:254-261, 1990.
 
5) Friedman PA, Gesek FA:Calcium transport in renal epithelial cells. Am J Physiol 33:F181-F198, 1993.
 
6) Bacskai BJ, Friedman PA:Activation of latent Ca2+ channels in renal epithelial cells by parathyroid hormone. Nature 347:388-391, 1990.
PubMed
7) Bouhiany I, Lajeunesse D, Brunette MG:The mechanisms of parathyroid hormone action on calcium reabsorption by the distal tubule. Endocrinology 128:251-258, 1991.
PubMed
8) Friedman PA:Cellular calcium transport in renal epithelial; measurement; mechanism and regulation. Physiol Rev 75:429-471, 1995.
PubMed
9) Takeda T, Arakawa M, Kuwano R:Organization and expression of the mouse spot 35/calbindin D28k gene; identh6cation of the Vitamin D responsive promotor region. Biochem Biophys Res Commun 204:889-897, 1994.
 
10) 杉本利嗣:Calcium-sensing receptor. リウマチ病セミナーX (. 七川歡次監修), pp242-251, 大阪, 永井書店, 1999.
 
11) Brown EM:A cloned extracellular Ca sensing receptor; molecular mediator of the action of extracellular Ca on parathyroid and kidney cells? Kidney Int 40:1042-1046, 1996.
 
12) DeRouffignac C:Renal magnesium handling and its hormonal control. Physiol Rev 74:305-322, 1994.
 
13) Hebert SC:Extracellular calciium-sensing receptor; implications for calcium and magnesium handling in the kidney. Kidney Int 50:2129-2139, 1996.
PubMed
14) Wang W:Two types of K+ channel in TAL of rat kidney. Am J Physiol 267:F599-F605, 1994.
PubMed
15) Kakeichi K, Uchida S, kurokawa K:High Ca2+ inhibits AVP-dependent cAMP production in thick acending limbs of Henle. Am J Physiol 250:F770-F776, 1986.
 
16) Brown EM, Pollak M, Hebert SC:The extracelular calcium-sensing receptor; its role in health and disease. Ann Rev Med 49:15-29, 1998.
 
17) Goldfrab S:Dietary factors in the pathogenesis and prophylatis of nephrolithiasis. Kidney Int 34:544-555, 1988
 
18) Ghazali A, Fuentes V, Desaint C, et al:Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 82:32-38, 1997.
PubMed
19) Mallmin H, Ljung-hall S, Persson I, et al:Risk factors for fractures of the distal forearm:a population-based case-control study. Osteoporosis Int 4:298-304, 1994.
 
20) Melton LJ, Crowson CS, Khosla S, et al:Fracture risk among patients with urolitiasis:a population-based cohort study. Kidney Int 53:459-464, 1998.
 
21) Bataille P, Achard JM, Fournier S, et al:Diet, Vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 39:1193-1205, 1991.
 
22) Pacifici R, Rothstein M, Rifas L, et al:Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. J Clin Endcrinol Metab 71:138-145, 1990.
 
23) Weisinger JR, Aonzo E, Bellorin-Font E, et al:Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 49:244-250, 1996.
 
24) Simon DB, Karet FE, Hamdan JM, et al:Bartte's syndrome hypokalemic alkalosis with hypercalciuria, is caused by mutations in the Na, K, 2C1 cotransporter NKCC2. Nature Genet 13:183-188, 1996.
 
25) Coe FL, Parks JH, Asplin JR:The pathogenesis and treatment of kidney stones. N Engl J Med 327:1141-1152, 1992.
PubMed
26) Ito S, Nozawa S, Ishikawa H, et al:Renal stones in patients with rheumatoid arthritis. J Rheumatol 24:2123-2128, 1999.
 
P.112 掲載の参考文献
1) Melton IJ, Riggs BL:Clinical spectrum. In; Osteoporosis (Eds, Riggs BL, Melton LJ III), pp155-179, New york, Raven Press, 1988.
 
2) Hall FM, Davis MA, Baran DT:Bone mineral screening for osteoporosis. N Engl J Med 316:212-214, 1987.
PubMed
3) 折茂 肇:骨粗鬆症, 図でみる骨粗鬆症, p4, 東京, メジカルビュー社, 1989.
 
4) Consensus Development Conference:diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650, 1992.
 
5) Hans D, Glu"er CC, Njeh CF:Ultrasonic evaluation of osteoporosis. Osteoporosis:Diagnosis and Management (Eds, Meunier PJ), pp59-78, London, Marttin Dunitz Ltd, 1998.
 
6) Kanis JA, Melton LJ III, Christiansen C, et al:The diagnosis of osteoporosis. J Bone Miner Res 9:1137-1141, 1994.
 
7) Miller PD, Harper KD:The World Health Organization Criteria for the diagnosis of osteoporosis should be endorsed. Osteoporosis Index & Reviews 1:2-5, 1996.
 
8) 藤田拓男:骨粗鬆症の疾患概念の変遷と定義. 日本臨牀 56:1363-1368, 1998.
Medical*Online
9) 伊丹康人, 大畠 嚢:骨粗鬆症の疫学と臨床. 日整会誌 38:487-489, 1964.
 
10) Sighn M, Nagrath AR, Naini PS:Change in trabecular pattern of the upper end of the femur as an index of osteoporosis. J Bone and Joint Surg 52A:457-462, 1973.
 
11) 折茂 肇, 中村哲郎:老人性骨粗鬆症の予防および治療に関する総合的研究・厚生省シルバーサイエンス研究 昭和63年度研究報告, pp81-82, シルバーサイエンス研究事務局, 大阪, 1989.
 
12) Peck WA, Burckhard P, Christiansen C, et al:Consensus development conference:Diagnosis prophylaxis and treatment of osteoporosis. Am J Med 94:646-650, 1993.
 
13) 折茂 肇:骨粗鬆症の予防に関する総合研究. 長寿科学総合研究報告 平成4年度研究報告vol 3, pp122-124, 長寿科学研究費中央事務局, 東京, 1993.
 
14) 折茂 肇, 杉岡洋一, 福永仁夫ら:原発性骨粗鬆症の診断基準 (1996年度改訂版). 日骨代謝誌14:219-235, 1997.
 
15) 折茂 肇:原発性骨粗鬆症の診断基準-2000年度改訂版 (概要). Osteoporosis 9:9-14, 2001.
 
16) 柏木大治:骨粗しょう症の名称について. わたしの旅老 整形外科医の雑感, pp225-227 , 旭成社, 2000.
 
17) 若松英吉, 日下部明, 佐藤光三ら:Osteoporosisの骨質の定量法. 臨整外4:856863, 1969.
 
18) Reifenstein EC Jr:Metabolic disorders of bone. In; Textbook of International Medicine, Sec 3 (Ed, Harrison TR), p651, Philadelphia, Blekiston, 1950.
 
19) 藤田拓男:骨粗鬆症概論-概念, 分類, 外国および本邦における疫学的事項-. 日本臨牀 52:2257-2280, 1994.
 

検査法

P.118 掲載の参考文献
1) Peterfy CG:Magnetic resonance imaging of rheumatoid arthritis:The evolution of clinical applications through clinical trials. Sem Arthritis Rheum 30:375-396, 2001.
 
2) McQueen F, Stewart N, Crabbe J, et al:Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals a high prevalence of erosions at four months after symptom onset. Ann Rheum Dis 57:350-356, 1998.
PubMed
3) Ostergaard M, Hansen M, Stolenberg M, et al:Magnetic resonance imaging-determined synovial membrane volume as a marker of disease activity and a predictor of progressive joint destruction in the wrists of patients with rheumatoid arthritis. Arthritis Rheum 42:918-929, 1999.
 
4) Durr HR, Stabler A, Maier M, et al:Pigmented villonodular synovitis. Review of 20 cases. J Rheumatol 28:1620-1630, 2001.
 
5) Peterfy CG, Majumdar S, Lang P, et al:MR imaging of the arthritic knee:improved discrimination of cartilage, synovium and effusion with pulsed saturation transfer and fat-suppressed T1-weighted sequences. Radiology 191:413-419, 1994.
PubMed
6) Ostergaard M, Klarlund M:Importance of timing of post-contrast MRI in rheumatoid arthritis:what happens during the first 60 minutes after IV gadolinium-DTPAP Ann Rheum Dis 60:1050-1054, 2001.
 
7) Bashir A, Gray ML, Burstein D:Gd-DTPA as a measure of cartilage degradation. Magn Reson Med 36:665-673, 1996.
PubMed
8) Palmer WE, Rosenthal DI, Shoenberg OI, et al:Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 196:645-655, 1995.
 
9) Sugimoto H, Takeda A, Kano S:Assessment of disease activity in rheumatoid arthritis using magnetic resonance imaging:quantification of pannus volume in the hands. Br J Rheumatol 37:854-861, 1998.
PubMed
10) McQueen F, Stewart N, Crabbe J, et al:Magnetic resonance imaging of the wrist in early rheumatoid arthritis reveals progression of erosions despite clinical improvement. Ann Rheum Dis 58:156-163, 1999.
PubMed
11) Ostergaard M, Stoltenberg M, Lovgreen-Neilsen P, et al:Quantification of synovitis by MRI:correlation between dynamic and static gadolinium-enhanced magnetic resonance imaging and microscopic and microscopic signs of synovial inflammation. Magn Reson Imaging 16:743-754, 1998.
 
P.125 掲載の参考文献
1) Brittberg M, Lindahl A, Peterson L:Treatment of deep cartilage defects in the knee With autologous chondrocyte transplantation. N Engl J Med 331:889-895, 1994.
PubMed
2) Peterson L, Brittberg M, Kiviranta I, et al:Autologous chondrocyte transplantation. Biomechanics and long-term durability. Am J Sports Med 30:2-12, 2002.
PubMed
3) Wakitani S, Imoto K, Yamamoto T, et al:Human autologous culture expanded bone marrow mesenchymal cell transplantation for repair of cartilage defects in osteoarthritis knees. Osteoarthritis Cartilage 10:199-206, 2002.
PubMed
4) Eckstein F, Schnier M, Haubner M, et al:Accuracy of canilage volume and thickness measurements with magnetic resonance imaging. Clin Orthop and Related Res 352:137-148, 1998.
 
5) 小松原良雄:軟骨保護薬. リウマチ病セミナーXIII (七川歡次監修), pp190-195, 大阪, 永井書店, 2002.
 
6) Speer KP, Spritzer CE, Goldner L, et al:Magnetic resonance imaging of traumatic knee articular cartilage infuries. Am J Sports Med 19:396-402, 1991.
 
7) Hodler J, Berthiaume M-J, Schwietzer ME, et al:Knee joint hyaline cartilage defects; A comparative study of MR and anatomic sections. J Comp Ass Tomography 16:597-603, 1992.
 
8) Levy AS, Lohnes J, Scully S, et al:Chondral delamination of the knee in soccer players. Am J Sports Med 24:634-639, 1996.
 
9) Disler DG, McCauley TR, Kelman CG, et al:Fat-suppressed three-dimensional spoiled gradient-echo MR imaging of hyaline cartilage defects in the knee; Comparison with standard MR imaging and arthroscopy. AJR 167:127-132, 1996.
PubMed
10) Mori R, Ochi M, Sakai Y, et al:Clinical significance of magnetic resonance imaging (MRI) for focal chonral lesions. Magn Res lmaging 17:1135-1140, 1999.
 
11) Recht MP, Piraino DW, Paletta GA, et al:Accuracy of fat-suppresed three-dimensional spoiled gradient-echo FLASH MR imaging in the detection of patellofemoral articular cartilage abnormalities. Radiology 198:209-212, 1996.
 
12) 中田 研, 濱田雅之, 前 達夫ら:関節軟骨のMRIによる評価; 3D-FS-FLASH法を用いて. 日整会誌75:254, 2001.
 
13) Potter HG, Linklater JM, Allen AA, et al:Magnetic resonance imaging of articular carilage in the knee. J Bone and Joint Surg 80-A:1276-1284, 1998.
 
14) 吉岡 大, 板井悠二:MTC画像. 画像診断14:39-47, 1994.
 
15) Bashir AG, Gray ML, Boutin RD, et al:Glycosaminoglycan in articular cartilage; in vivo assessment with delayed Gd-(DTPA) 2-enhanced MR imaging. Radiology 205:551-558, 1997.
 
16) Brossmann J, Frank LR, Pauly JM, et al:Short echo time projection reconstruction MR imaging of cartilage; comparison with fat-suppressed spoiled GRASS and magnetization transfer contrast MR imaging. Radiology 203:501-507, 1997.
PubMed
17) Insko EK, Reddy R, Leigh JS:Hith resolution, short echo time sodium imaging of articular cartilage. J Magn Reson Imaging 7:1056-1059, 1997.
 
18) Rubenstein JD, Li JG, Majumdar S, et al:Image resolution and signal-to-noise ratio requirement or MR imaging of degenerative cartilage. AJR 169:1089-1096, 1997.
PubMed
P.130 掲載の参考文献
1) Inoue T, Kim EE, Franklin CL, et al:Comparison of fluorine-18-fiuorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors. J Nucl Med 37:1472-1476, 1996.
 
2) Kole AC, Nieweg OE, Hoekstra HJ, et al:Fluorine-18fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 39:810-815, 1998.
 
3) Watanabe H, Shinozaki T, Yanagawa T, et al:Glucose metabolic analysis of musculoskeletal tumors using 18 fluorine-FDG PET as an aid to preoperative planning. J Bone J Surg 82-B:760-767, 2000.
 
4) Jones DN, McCowage GB, Sostman HD, et al:Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using Fluorine-18FDG PET. J Nucl Med 37:1438-1444, 1996.
 
5) Uchida K, Yoshizawa K, Baba H, et al:Clinical application of a high-resolution positron emission tomography for cervical spinal cord lesions. Orthop Surg Traumatol 42:1347-1352, 1999.
 
6) Tashiro M, Fujimoto T, Itoh M, et al:18F-FDG PET imaging of muscle activity in runners. J Nucl Med 40:70-76, 1999.
PubMed
7) Yasuda S, Shohtsu A, lde M, et al:F-18 FDG Accumulation in inflamed joints. Clin Nucl Med 21:740, 1996.
 
8) Guhlmann A, Brecht-Kraus D, Suger G, et al:Chronic osteomyelitis:detection with FDG-PET and correlation with histopathologic findings. Radiology 206:749-754, 1998.
 
9) Winter FD, Wiele CV, Vogelaers D, et al:Fluorine-18 fluorodeoxyglucose-positron emission tomography:A highly accurate imaging modality for the diagnosis of chronic musculoskeletal infections. J Bone J Surg 83-A:651-660, 2001.
 
10) Zhao S, Kuge Y, Tsukamoto E, et al:Effects of insulin and glucose loading on FDG uptake in experimental malignant tumors and inflammatory lesions. Eur J Nucl Med 28:730-735, 2001.
PubMed
11) Palmer WE, Rosenthal DI, Schoenberg OI, et al:Quantification of inflammation in the wrist with gadolinium-enhanced MR imaging and PET with 2-(F-18)-fluoro-2-deoxy-D-glucose. Radiology 196:647-655, 1995.
 
12) Richard PP, Oded IS, Schoenberg AF, et al:Use of magnetic resonance imaging and positron emission tomography in the assessment of synovial volume and glucose metabolism in patients With rheumatoid arthritis. Arthritis Rheum 38:819-825, 1995.
 

生物学的反応

P.134 掲載の参考文献
1) Pittenger MF, Mackay AM, Beck SC, et al:Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147, 1999.
PubMed
2) Williams JT, Southerland SS, Souza J, et al:Cells isolated from adult human skeletal muscle capable of differentiating into multiple mesodermal phenotypes. Am Surg 65:22-26, 1999.
PubMed
3) Kuznetsov SA Mankani MH, Gronthos S, et al:Circulating skeletal stem cells. J Cell Biol 153:1133-1140, 2001.
PubMed
4) Zuk PA, Zhu M, Mizuno H, et al:Multilineage cells from human adipose tissue; implications for cell-based therapies. Tissue Eng 7:211-228, 2001.
PubMed
5) Kopen GC, Prockop DJ, Phinney DG:Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci USA 96:10711-11716, 1999.
PubMed
6) Petersen BE, Bowen WC, Patrene KD, et al:Bone marrow as a potential source of hepatic oval cells. Science 284:1168-1170, 1999.
PubMed
7) Barry FP, Boynton RE, Haynesworth S, et al:The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem Biophys Res Commun 265:134-139, 1999.
PubMed
8) Zhou S, Schuetz JD, Bunting KD, et al:The ABC transporter Bcrp1/ABCG2 is expressed in a Wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 7:1028-1034, 2001.
 
9) Storm EE, Kingsley DM:Joint patteming defects caused by single and double mutations in members of the bone morphogenetic protein (BMP) family. Development 122:3969-3979, 1996.
PubMed
10) Hartmann C, Tabin CJ:Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton. Cell 104:341-351, 2001.
 
11) Sen M, Lauterbach K, El-Gabalaw H, et al:Expression and function of wingless and frizzled homologs in rheumatoid arthritis. Proc Natl Acad Sci USA 97:2791-2796, 2000.
 
12) Marinova-Mutafchieva L, Taylor P, Funa K et al:Mesenchymal cells expressing bone morphogenetic protein receptors are present in the rheumatoid arthritis joint. Arthritis Rheum 43:2046-2055, 2000.
PubMed
13) Zvaifler N:Mesenchymal stem cell, a new kid in the joint. XVIIe Journee de Rhumatologie de l'Hopital Cochin. Infections et rhumatismes, pp2-3, 28 Mars 2001, Bruno Thomasset.
 
14) Nakagawa S, Toritsuka Y, Wakitani S, et al:Bone marrow stromal cells contribute to synovial cell proliferation in rats with collagen induced arthritis. J Rheumatol 23:2098-2103, 1996.
PubMed
P.139 掲載の参考文献
1) 佐伯行彦:破骨細胞の形成と機能発現. 破骨細胞の分化/成熟と骨吸収の分子機構. リウマチ病セミナーXII (七川歡次監修), pp183-189 , 大阪, 永井書店, 2001.
 
2) Tsuda E, Goto M, Mochizuki S, et al:Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234:137-142, 1997.
PubMed
3) Simonet WS, Lacey DL, Dunstan CR, et al:Osteoprotegerin; a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997.
PubMed
4) Yamaguchi K, Kinosaki M, Goto M, et al:Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem 273:5117-5123, 1998.
PubMed
5) Suda T, Takahashi N, Martin TJ:Modulation of osteoclast differentiation. Endocr Rev 13:66-80, 1992.
PubMed
6) Lacey DL, Timms E, Tan HL, et al:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998.
PubMed
7) Yasuda H, Shima N, Nakagawa N, et al:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602, 1998.
PubMed
8) Wong BR, Rho J, Arron J, et al:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem 272:25190-25194, 1997.
 
9) Anderson DM, Maraskovsky E, Billingsley WL, et al:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997.
PubMed
10) Kong YY, Yoshida H, Sarosi I, et al:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999.
PubMed
11) Hsu H, Lacey DL, Dunstan CR, et al:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96:3540-3545, 1999.
PubMed
12) Mizuno A, Amizuka N, Irie K, et al:Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247:610-615, 1998.
PubMed
13) Bucay N, Sarosi I, Dunstan CR, et al:Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12:1260-1268, 1998.
PubMed
14) Takayanagi H, Iizuka H, Juji T, et al:Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43:259-269, 2000.
PubMed
15) Kong YY, Feige U, Sarosi I, et al:Activated T cells regulate bone loss and joint destuction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999.
 
16) Bekker PJ, Holloway D, Nakanishi A, et al:The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res 16:348-360, 2001.
PubMed

治療と副作用

P.145 掲載の参考文献
1) Levy M, Miller DR, Kaufman DW, et al:Major upper gastrointestinal tract bleeding. Relation to the use of aspirin and other nonnarcotic analgesics. Arch Intem Med 148:281-285, 1988.
 
2) Singh G:Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 105 (1B):31S-38S, 1995.
 
3) 塩川優一ら:-日本リウマチ財団委員会報告-非ステロイド性抗炎症剤による上部消化管傷害に関する疫学調査. リウマチ31:96-111, 1991.
 
4) Fries JF, Williams CA, Bloch DA:The relative toxicity of nonsteroidal anti-inflammatory drugs. Arthritis and Rheum 34:1353-1360, 1991.
PubMed
5) Aderem AA, Cohen DS, Wright SD, et al:Bacterial lipopolysaccharides prime macrophages for enhanced release of arachidonic acid metabolites. J Exp Med 164:165-179, 1986.
PubMed
6) Kurland JI, Bockman R:Prostaglandin E production by human blood monocytes and mouse peritoneal macrophages. J Exp Med 147:952-957, 1978.
PubMed
7) Masfe rrer JL, Zweifel BS, Seibert K, et al:Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 86:1375-1379, 1990.
 
8) Vane JB:Inhibition of pro staglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature New Biol 231:232-235, 1971.
 
9) Smith CJ, Morrow JD, Robert IJ, et al:Differentiation of monocytoid THP-1 cells with phorbol ester induces expression of prostaglandin endoperoxide synthase-1 (COX-1). Biochemical and Biophysical research communications 19:787-193, 1993.
 
10) Crofford LJ:Cox-1 and cox-2 tissue espression:implications and predictions. J Rheumatol 24:15-19, 1997.
 
11) Siegle I, Klein T, Backman JT, et al:Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue. Differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 41:122-129, 1998.
PubMed
12) Crofford LJ, Wilder RL, et al:Cyclooxygenase-1 and-2 expression in rheumatoid synovial tissues, Effects of Interleukin-1b, phorbol ester, and corticosteroids. J Clin Invest 93:1095-1101, 1994.
 
13) Sano H, Hla T, Majier JAM, et al:In vivo cyclooxygenase expression in synovial tissues of patients with rheumatoid arthritis and osteoarthritis and rats with adjuvant and streptococcal cell wall arthritis. J Clin Invest 89:97-108, 1992.
 
14) Szczepanski A, Moatter T, Carley WW, et al:Induction of cyclooxygenase II in human synovial microvessel endothelial cells by interleukin-1:Inhibition by glucocorticoids. Arthritis Rheum 37:495-503, 1994.
 
15) Picot D, Loll PJ, Garavito RM:The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 367:243-249, 1994.
 
16) Luong C, Miller A, Bamett J, et al:The structure of human cyclooxygenase-2; conservation and flexibility of the NSAID binding site. Nat Struct Biol 3:927-933, 1996.
 
17) The international COX-2 Study Group:The classification of cyclooxygenase inhibitors. J Rheumatol 25:2298-2303, 1998.
 
18) Portanova JP, Zhang Y, Anderson GD, et al:Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 184:883-891, 1996.
PubMed
19) 近藤啓文:日本医師会雑誌122:EI22-24, 1999.
 
20) Smith CJ, Zhang Y, Koboldt CM, et al:Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci USA 95:13313-13318, 1998.
PubMed
21) Vane JR, et al:Cyclooxygenase l and 2. Ann Rev Pharmacol Toxicol 38:97-120, 1998.
 
22) Simon LS, Lanza FL, Lipsky PE, et al:Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Ethcacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects. Arthritis and Rheum 41:1591-1602, 1998.
PubMed
23) Berenbaum F:Selective cyclooxygenase-2 inhibitors; hope and facts. Joint Bone Spine 67:499-501, 2000.
PubMed
24) Bombardier C, laine L, Reicin A:Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528, 2000.
PubMed
25) Silverstein FE, Faich G, Goldstein JL, et al:Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. JAMA 284:1247-1255, 2000.
PubMed
26) Emery P, Zeidler H, Kvien TK, et al:Celecoxib versus diclofenac in long-term management of rheumatoid arthritis:randomized double-blind comparison. Lancet 354:2106-2111, 1999.
PubMed
27) Hawkey C, Kahan A, Steinbruck K, et al:Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. British Journal of Rheumatology 37:937-945, 1998.
PubMed
28) Komhoff M, Grone H-J, Klein T, et al:Localization of cyclooxygenase-1 and-2 in adults and fetal human kidney:implication for renal function, Am J Physiol 272:F46 (F466, 1997.
 
29) Harris RC, Mckanna JA, Akai Y, et al:Cyclooxygenase-2 is associated With the macula densa of rat kidney and increases with salt restriction. J Clin Invest 94:2504-2510, 1994.
PubMed
30) Grofford LJ, Oates JC, McCune WJ, et al:Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors. A report of four cases. Arthritis and Rheum 43:1891-1896, 2000.
 
31) Thun MJ, et al:Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593-1596, 1991.
PubMed
32) Kargman SL, et al:Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res 55:2556-2559, 1995.
PubMed
33) Mcgeer PL, et al:Arthritis and antiinflammatory agents possible protective factor for Alzheimer's disease:a review of 17 epidemiologic studies. Neurology 47:425-432, 1996.
PubMed
P.153 掲載の参考文献
1) Relman AS:Assessment and accountability; the third revolution of medical care. New Engl J Med 319:1220-1222, 1988.
PubMed
2) 李 啓充:市場原理に揺れるアメリカの医療, 東京, 医学書院, 1998.
 
3) 李 啓充:アメリカ医療の光と影, 東京, 医学書院, 2000.
 
4) Donabedian A:Evaluating the quality of medical care. Milbank Memorial Fund Quartery 44:166-246, 1966.
 
5) 前谷俊三::診療録におけるアウトカム志向型システム. Tenri Medical Bulletin 3:44-54, 2000.
Medical*Online
6) Sackett DL, Straus SE, Richaardson WS, et al:Evidence-based medicine; How to practice and teach EBM, 2nd Ed, London, Churchill Livingstone, 2000.
 
7) 天理ようづ相談所医学統計解析グループ:証拠に基づく医療 (Evidence-based medicine):その妥当性と限界. Tenri Medical Bulletin 3:138-153, 2000.
 
8) 天理ようづ相談所医学統計解析グループ:情報の価値からみた医学統計学の再検討. 臨床評価27:393-407, 1999.
 
9) Gardner MJ, Altman DG:Confidence intervals rather than P values; estimation rather than hypothesis testing. Br Med J 292:746-750, 1986.
 
10) Laupacis A, Sackett DL, Roberts RS:An assessment of clinically useful measure of the consequences of treatment. New Engl J Med 318:172&1733, 1988.
 
11) 前谷俊三, 飯島庸介, 戸部隆吉:直腸癌における拡大根治手術とその評価. 外科47:147-152, 1985.
 
12) 天理ようづ相談所医学統計解析グループ:臨床側からみた生存分析:Coxモデルから新しい生存モデルへ. 天理医学紀要4:128-146, 2001.
 
13) Maetani S, Yamazoe Y, Onodera H, et al:Estimation of mean survival time from limited follow-up in cancer patients. Tenri Medical Bulletin 1:38-49, 1998.
 
14) Maetani S, Matsusue S:Mean survival time in gastric cancer patients estimated from a parametric model; comparison with long-term follow-up results. Tenri Medical Bulletin 3:15-25, 2000.
 
15) Maetani S, Nakajima T:30-to 50-year follow-up of gastric cancer patients. Are the results predictable five years after surgery? Proceedings of the 4-th International Gastric Cancer Congress, Munduzzi Editore, Bologna, 2001.
 
16) Tan LB, Murphy R:Shifts in mortality curves:saving or extending lives? Lancet 354:1378-1381, 1999.
PubMed
17) Wright JC, Weinstein MC:Gains in life expectancy from medical interventions; standardizing data on outcomes. New Engl J Med 339:280-286, 1998.
 
18) Lubsen J, Hoes A, Grobbee D:Implications of trial results; the potentially misleading notions of number needed to treat and average duration of life gained. Lancet 356:1757-1756, 2000.
PubMed
19) Boag JW:Maximum likelihood estimates of the proponion of patients cured by cancer therapy. J Roy Statist Soc B11:15-53, 1949.
 
20) Peto R, Pike MC, Armitage P, et al:Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br J Cancer 34:585-612, 1976.
PubMed
21) Wright V:Measurement of outcome in rheumatic diseases. J Roy Soc Med 78:985-994, 1985.
PubMed
22) Neumann J, Morgenstern O:Theory of games and economic behavior. Princeton University Press, 1947.
 
23) 前谷俊三:臨床生存分析:生存価値の評価と比較, pp81-100, 東京, 南江堂, 1996.
 
24) Greenfield S:The state of outcome research; are we on target? New Engl J Med 320:1142-1143, 1989.
PubMed
P.161 掲載の参考文献
1) M Michael Wolfe MM, Lichtenstein DR, Singh G:Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 340:1888-1899, 1999.
 
2) 平石秀幸, 吉浦健太, 寺野 彰:NSAIDs起因性胃病変. Mebio 18:38-43, 2001.
 
3) 柳川 明, 遠藤 徹:NSAIDsによる胃十二指腸潰瘍発生頻度推移. Mebio 18:32-37, 2001.
 
4) Chan FK, Wu JC, Yung MY, et al:Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term non-steroidal anti-inflammatory drugs:arandomized trial. Lancet 359:9-13, 2002.
 
5) Page J, Henry D:Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 160:777-784, 2000.
PubMed
6) Heerdink ER, Leufkens HG, Herings RMC, et al:NSAIDs associated with increased risk of congestive heart failure in eldtaking diuretics. Arch Intem Med 158:1108-1112, 1998.
 
7) Catella-Lawson F, Reilly MP, Kapoor SC, et al:Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345:1809-1817, 2001.
PubMed
8) Mukheriee D, Nissen SE, Topol EJ:Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA Aug 286:954-959, 2001.
 
9) 安波礼子:COX-2 selective inhibitorの期待と現実. リウマチ病セミナーXIII (七川歡次監修), pp141-146, 大阪, 永井書店, 2002.
 
10) Lippman2 SM, Hong W:Cancer prevention science and practice 1. Cancer Res 62:5119-5125, 2002.
 
11) Giardiello FM, Hamilton SR, Krush AJ, et al:Treatment of colcnic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328:1313-1316, 1993.
PubMed
12) 美馬 亨:Cox-2 inhibitor. リウマチ病セミナーIX (七川歡次監修), pp147-154, 大阪, 永井書店, 1998.
 
13) Steinbach G, Lynch PM, Phillips RKS, et al:The effect of Celecoxib, a cyclooxigenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:19461952, 2000.
 
14) Breitner JCS, Gau BA, Welsh KA, et al:Inverse association of anti-inflammatory treatments and Alzheimerﾕs desease. Neurology 44:227-232, 1994.
 
15) Rogers J, Kirby LC, Hempelman SR, et al:Clinical trial of indomethacin in Alzheimerﾕs disease. Neurology 43:1609-1611, 1993.
 
16) Hull M, Lieb K, Fiebich BL:Pathway of inflammatory activation in Alzheimerﾕs disease modifying drugs. Curr Med Chem 9:83-88, 2002.
 
17) Jiang C, Ting AT, Seed B:PPAR-γ agonist inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998.
 
18) Yin MJ, Yamamoto Y, Gainor RB:The anti-inflammatory agents aspirin and salicylate inhibit the activity of Iκ B kinase-B. Nature 396:77-80, 1998.
 
19) Stevenson DD, Simon RA:Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 108:47-51, 2001.
PubMed
20) Chandrasekharan NV, Dai H, Roos KL, et al:Cox-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs:Cloning, structure, and expression. Proc Natl Acad Sci USA (in press).
 
P.166 掲載の参考文献
1) Ikehara S, Good RA, Nakamura T, et al:Rationale for bone marrow transplantation in the treatment of autoimmune diseases. Proc Natl Aca Sci USA 82:2483-2487, 1985.
 
2) Kushida T, Inaba M, Takeuchi K, et al:Treatment of intractable autoimmune diseases in MRL/lpr mice using a new strategy for allogeneic bone marrow transplantation. Blood 95:1862-1868, 2000.
PubMed
3) Kushida T, Inaba M, Hisha H, et al:Intrabone marrow injection of allogeneic bone marrow cells:A powerful new strategy for treatment of intractable autoimmune diseases in MRL/lpr mice. Blood 97:3292-3299, 2001.
PubMed
4) Kushida T, lnaba M, Ikebukuro K et al:A new method for bone marrow cell harvesting. Stem Cells 18:453-456, 2000.
 
5) Ikehara S, Yasumizu R, Inaba M, et al:Long-term observations of autoimmune-prone mice treated for autoimmune disease by allogeneic bone marrow transplantation. Proc Natl Acad Sci USA 86:33063310, 1989.
 
6) Doi H, Inaba M, Yamamoto Y, et al:Pluripotent hemopoietic stem cells are c-kit<low. Proc Natl Acad Sci USA 94:2513-2517, 1997.
 
7) Sugiura K, Inaba M, Ogata H, et al:Whea germ agglutinin-positive cells in a stem cell-enriched fraction of mouse bone marrow have poten natural suppressor activity. Proc Natl Acad Sci USA 85:4824-4826, 1988.
 
8) Ishida T, Inaba M, Hisha H, et al:Requirement of donor-derived stromal cells in the bone marrow for successful allogeneic bone marrow transplantation; complete prevention of recurrence of autoimmune diseases in MRL/MP-lpr/lpr mice by transplantation pf bone manpw plus bone (stromal cells) from the same donor. J Immunol 152:3119-3127, 1994.
 
9) Hashimoto F, Sugiura K, lnoue K, et al:Major histocompatibility complex restriction between hematopoietic stem cells and stromal cells in vivo. Blood 89:49-54, 1997.
 
10) Takeuchi K, Inaba M, Miyashima S, et al:A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood 91:4616-4623, 1998.
PubMed
11) Zhang Y, Yasumizu R, Sugiura K, et al:Fate of allogeneic or syngeneic cells in intravenous or portal vein injection; possible explanation for the mechanism of tolerance induction by portal vein injection. Eur J lmmunol 24:1558-1565, 1994.
 
12) Sugitlra K, Kato K, Hashimoto F, et al:Induction of donor-specific T cell anergy by portal venous injection of allogeneic cells. lmmunobiol 197:460-477, 1997.
 
13) Kushida T, Inaba M, Hisha H, et al:Crucial role of donor-derived stromal cells in successful treatment for intractable autoimmune diseases in MRL/lpr mice by BMT via portal vein. Stem Cells 19:226-235, 2001.
 
14) Marmont AM:Immune ablation and stem cell therapy; A new treatment for severe autoimmune disease? Stem Cells 12:125-135, 1994.
 
15) Tyndall A:Hematopoietic stem cell transplantation in rheumatic diseases other than systemic sclerosis and systemic lupus erythematosus. J Rheumatol 24:94-97, 1997.
 
16) Loske DJL:Autologous bone-marrow transplantation for rheumatoid arthrits. Lancet 350:337-338, 1997.
 
17) Burt RK, Bums W, Hess A:Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplantation 16:1-6, 1995.
 
18) van Gelder M, van Bekkum DW:Treatment of relapsing experimental autoimmune encephalomyelitis in rats with allogeneic bone marrow transplantation from a resistant strain. Bone Marrow Transplantation 16:343-351, 1995.
PubMed
19) Karussis DM, Slavin S, Ben-Nun A, et al:Chronic-relapsing experimental autoimmune encephalomyelitis (CR-EAE):treatment and induction of tolerance with high-dose cyclophosphamide followed by syngeneic bone marrow transplantation. J Neuroimmnol 39:201-210, 1992.
PubMed
20) Euler HH, Marmont AM, Bacigalupo A, et al:Early recurrence or persistence of autoimmne diseases after unmanipulated autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 88:3621-3625, 1996.
PubMed
21) Ikehara S:Treatment of autoimmune diseases by hematopoietic stem cell transplantation. Exp Hematol 29:661-669, 2001.
PubMed
22) Li Y, Hisha H, lnaba M, et al:Evidence for migration of donor bone marrow stromal cells into recipient thymus after bone marrow transplantation plus bone grafts:A role of stromal cells in positive selection. Exp Hematol 28:950-960, 2000.
 
P.173 掲載の参考文献
1) 豊島 元, 草場公宏, 山口雅也ら:剖検輯報からみた慢性関節リウマチの死因-とくにアミロイドーシスとの関連から. リウマチ33:209-214, 1993.
 
2) 吉沢久嘉, 工藤 洋, 岩野邦男ら:慢性関節リウマチの死因に関する研究. リウマチ30:255-263, 1990.
 
3) 大田 寛:慢性関節リウマチ患者の死因と寿命. リウマチ病セミナーIII (:七川歡次監修), pp85-94, 大阪, 永井書店, 1992.
 
4) 中井秀紀, 尾崎承一, 狩野庄吾ら:多施設研究による本邦の慢性関節リウマチに合併する続発性アミロイドーシスの臨床的特徴と遺伝的背景. リウマチ36:25-33, 1996.
 
5) Nakano M, Ueno M, Nishi S, et al:Analysis of renal pathology and drug history in 158 Japanese patients With rheumatoid arthritis. Clin Nephrol 50:154, 1998.
PubMed
6) 奥田恭章, 高杉 潔:アミロイドーシス合併RAの早期診断と予後. リウマチ科21:460-465, 1999.
 
7) 松田剛正:消化管アミロイドーシス. リウマチ科21:446-450, 1999.
 
8) Baba S, Masago SA, Takahashi T, et al:A novel allelic variant of serum amyloid A, SAA 1 γ:genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum Mol Genet 4:1083-1087, 1995.
 
9) 馬場聡:血清アミロイドA (SAA) 多型とAA-アミロイドーシス-新しく発見されたSAA1γはAA-アミロイドーシスの危険因子である-, リウマチ病セミナーIX (七川歡次監修), pp131-137, 大阪, 永井書店, 1998.
 
10) Baba S, Nakai H, Nakamtlra T, et al:Novel polymorphisms in the 5'flanking region of the human serum amyloid al (SAA 1) gene and an association with reactive AA-amyloidosis. Amyloid and Amyloidosis 2001 (in press) .
 
11) 香坂隆夫, 河合忠, 伊藤喜久ら:ラテックス凝集免疫測定法による血清アミロイドA (SAA) 測定の臨床的検討. 医学と薬学31:1191-1210, 1994.
 
12) 山田俊幸:リコンビナントSAA 1アイソタイプの作製と応用 (第44回日本リウマチ学会総会・学術集会抄録集) . リウマチ40:389, 2000.
 
P.177 掲載の参考文献
1) Elliot MJ, Maini RN, Feldmann M, et al:Treatment of rheumatoid arthritis With chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum 36:1681-1690, 1993.
 
2) Hamilton J, Capell H:The treatment of juvenile arthritis. Expert Opin Pharmacother 2:1985-1992, 2001.
 
3) Brandt J, Haibel H, Reddig J, et al:Succesful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 29:118-122, 2002.
 
4) Brandt J, Haibel H, Sieper J, et al:Infliximab treatment of severe ankylosing spondylitis:one-year follow up. Arthritis Rheum 44:2939, 2001.
 
5) Boeger CA, Wittwer H, Schattenkirchner M, et al:Treatment of ankylosing spondylitis with infliximab. Ann Rheum Dis 60:1159-1160, 2001.
PubMed
6) Brandt J, Haibel H, Comely D, et al:Succesful treatment of active ankylosing spondylitis with the anti-tumornecrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43:1346-1356, 2000.
 
7) Cavagna I, Caporali R, Epis O, et al:Infliximab in the treatment of adult Still's disease refractory to conventional therapy. Clin Exp Rheumatol 19:329-332, 2001.
 
8) Chey WY, Hussain A, Ryan C, et al:Infliximab for refractory ulcerative colitis. Am J Gastroenterol 96:2373-2381, 2001.
PubMed
9) Chey WY:Infliximab for patients with refractory ulcerative colitis. Inflamm Bowel Dis Suppl 1:S30-33, 2001.
 
10) Travis SP, Czalkowski M, McGovern DP, et al:Treatment of interstinal Behcet's syndrome with chimeric tumor necrosis factor alpha antibody. Gut 49:725-728, 2001.
 
11) Sfikakis PP, Theodossiadis PG, Katsiari CG, et al:Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 358:295-296, 2001.
PubMed
12) Goossens PH, Verburg RJ, Breedveld FC:Remission of Behcet's syndrome with tumor necrosis factor alpha blocking therapy. Ann Rheum Dis 60:637, 2001.
PubMed
13) Hughes AP, Jackson JM, Callen Jp:Clinical features and treatment of peristomal pyiderma gangrenosum. JAMA 284:1546-1548, 2000.
PubMed
14) Tan MH, Gordon M, Lebwohl O, et al:Improvement of pyoderma gangrenosum and psoriasis associated with Crohn's disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 137:930-933, 2001.
PubMed
15) Wiendl H, Neuhaus O, Kappos L, et al:Multiple sclerosis. Current review of failed and discontinued clinical trials of drug treatment. Nervenarzt 71:597-610, 2000.
PubMed
16) Chaudhari U, Romano P, Mulcahy LD, et al:Efiicacy and safety of infliximab monotherapy for plaque-type psoriasis:a randomized trial. Lancet 357:1842-1847, 2001.
 
17) Kirby B, Marsland AM, Carmichael AJ, et al:Succesful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate. Clin Exp Dermatol 26:27-29, 2001.
 
18) Ogilvie AL, Antoni C, Dechani C, et al:Treatment of psoriatic arthritis with antitumor necrosis factor-alpha antibody clears skin lesions of psoriasis resistant to treatment With methotrexate. Br J Dermatol 144:587-589, 2001.
 
19) Baughman RP, Lower EE:Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 18:70-74, 2001.
PubMed
20) Steifeld SD, Demols P, Salmon I, et al:Infliximab in patients with primary Sjogren's syndrome:a pilot study. Arthritis Rheum 44:2371-2375, 2001.
 
21) Kobbe G, Schneider P, Rohr U, et al:Treatment of severe steroid refractory acute graft-versus-host disease with inflimab, a chimeric human/mouse anti-TNF alpha antibody. Bone Marrow Transplant 28:47-49, 2001.
 
22) Infliximab chimeric anti-tumor necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndrome. Br J Haematol 116:334-337, 2002.
 
23) Derkx B, Taminiau J, Radema S, et al:Tumor necrosis factor antibody treatment in Crohn's disease [letter]. Lancet 342:173-174, 1993.
PubMed
24) Targan SR, Hanauer SB, van Deventer SJH, et al:Ashort-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 337:1029-1038, 1997.
 
25) Rutgeers P, D'Haens G, Targan S, et al:Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (Infliximab) to maintain remission in Crohn's disease. Gastroentrology 117:761-769, 1999.
 
26) Present DH, Rutgeerts P, Targan S, et al:Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:13981404, 1999.
 
27) Soykan I, Erian C, Ozden A. Severe anaphylactic reaction to infliximab:report of a case. Am J Gastroenterology 95:2395-2396, 2000.
 
28) Keane J, Gershon S, Wise RP, et al:Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098-1101, 2001.
PubMed
P.187 掲載の参考文献
1) Totoritis MC, Rosenberg J, Sklenar TA, et al:Phase I Clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 28:95-101, 2001.
PubMed
2) Alvarez-Nemegyei J, Cobarrubias-Cobos A, Escalante-Triay F, et al:Bromocriptine in systemic lupus erythematosus. A double-blind, randomized, placebo-controlled study. Lupus 7:414-419, 1998.
PubMed
3) Walker SE, McMurray RW, Houri JM, et al:Effects of prolactin in stimulating desease activity in systemic lupus erythematosus. Ann NY Acad Sci 840:762-772, 1998.
 
4) Barry NN, McGuire JL, van Vollenhoven RF, et al:Dehydroepiandrosterone in systemic lupus erythematosus relationship between dosage, serum levels, and clinical response. J Rheumatol 25:2352-2356, 1998.
PubMed
5) van Vollenhoven RF, Morabito LM, Engleman EG, et al:Treatment of systemic lupus erythematosus with dehydroepiandrosterone 50 patients treated up to 12 months. J Rheumatol 25:285-289, 1998.
PubMed
6) van Vollenhoven RF, Park JL, Genovese MC, et al:A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus 8:181-187, 1999.
PubMed
7) McMurray RW, Elbourne KB, Lagoo A, et al:Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZBxNZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 25:2364-2370, 1998.
 
8) Jonsson CA, Erlandsson M, Svensson L, et al:Mycophenolate mofetil ameliorates perivascular T lymphocyte inflammation and reduces the double-negative T cell population in SLE-prone MRLpr/lprmice. Cell Immunol 197:136-144, 1999.
 
9) Gaubitz M, Schorat A, Schotte H, et al:Mycophenolate mofetil for the treatment of systemic lupus erythematosus; an open pilot trial. Lupus 8:731-736, 1999.
PubMed
10) Glicklich D, Acharya A:Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 32:318-322, 1998.
PubMed
11) Davis JC Jr, Manzi S, Yarboro C, et al:Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 8:68-76, 1999.
PubMed
12) Pan CQ, Dodge TH, Baker DL, et al:Improved potency of hyperactive and actin-resistant human Dnase I variants for treatment of cystic fibrosis and systemic lupus erythematosus. J Biol Chem 273:18374-18381, 1998.
PubMed
13) Levy Y, Sherer Y, Ahmed A, et al:A study of 20 SLE patients with intravenous immunolobulin-clinical an serologic response. Lupus 8:705-712, 1999.
 
14) Arahata H, Migita K, Izumoto H, et al:Successful treatment of rapidly progressive lupus nephritis associated with anti-MPO antibodies by intravenous immunoglobulins. Clin Rheumatol 18:77-81, 1999.
PubMed
15) Sherer Y, Levy Y, Shoenfeld Y:Marked improvement of severe cardiac dysfunction after one course of intravenous immunoglobulin in a patient with systemic lupus erythematosus. Clin Rheumatol 18:238-240, 1999.
 
16) Heyneman CA, Gudger CA, Beckwith JV:Intravenous immune globulin for inducing remissions in systemic lupus erythematosus. Ann Pharmacother 31:242-244, 1997.
PubMed
17) Duddridge M, Powel RJ:Treatment of severe difficult cases of systemic lupus erythematosus with facrolimus. Areport of three cases. Am Rheum Dis 56:690-692, 1997.
 
18) Strand V:Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus. Curr Opin Rheumatol 11:330-340, 1999.
PubMed
19) Petri M, Genovese M, Engle E, et al:Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 34:937-944, 1991.
PubMed
20) Laitman RS, Glicklich D, Sablay LB, et al:Effect of long-term normalization of serum complement levels on the course of lupus nephritis. Am J Med 87:132-138, 1989.
PubMed
21) Milis L, Timmermans V, Morris CA, et al:The value of complement measurements in the assessment of lupus activity. Aust NZ J Med 22:338-344, 1992.
 
22) ter Borg EJ, Horst G, Hummel EJ, et al:Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33:634-643, 1990.
PubMed
23) Bombardier C, Gladman DD, Urowitz MB, et al:A disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992.
PubMed
24) Abu-Shakra M, Urowitz MB, Gladman DD, et al:Mortality studies in systemic lupus erythematosus. Results from a single center. II. Predictor variables for mortality. J Rheumatol 22:1265-1270, 1995.
PubMed
25) Liang MH, Socher SA, Larson MG, et al:Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 32:1107-1118, 1989.
PubMed
26) Symmons DP, Coppock JS, Bacon PA, et al:Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). QJMed 69:927-937, 1988.
PubMed
27) Gladman DD, Goldsmith CH, Urowitz MB, et al:Sensitivity to change of 3 Systemic Lupus Erythematosus Disease Activity Indices; international validation. J Rheumatol 21:1468-1471, 1994.
 
28) Janssen BA, Luqmani RA, Gordon C, et al:Correlation of blood levels of soluble vascular cell adhesion molecule-1 with disease activity in systemic lupus erythematosus and vasculitis. Br J Rheumatol 33:1112-1116, 1994.
PubMed
29) Linker-lsraeli M, Hyun S, Ozeri-Chen T, et al:Elevated in vivo and in vitro secretion of CD8-alpha molecules in patients with systemic lupus erythematosus. J Immunol 152:3158-3167, 1994.
 
30) Siegert CE, Daha MR, Tseng CM, et al:Predictive value of IgG autoantibodies against C1q for nephritis in systemic lupus erythematosus. Ann Rheum Dis 52:851-856, 1993.
PubMed
31) Elkayam O, Tamir R, Pick AI, et al:Serum IgE concentrations, disease activity, and atopic disorders in systemic lupus erythematosus. Allergy 50:94-96, 1995.
PubMed
32) Atta MS, Lim KL, Alaideen DA, et al:Investigation of the prevalence and clinical associations of antibodies to human fibronectin in systemic lupus erythematosus. Ann Rheum Dis 54:117-124, 1995.
 
33) Hayball PJ, Cosh DG, Ahem MJ, et al:High dose oral methylprednisolone in patients with rheumatoid arthritis; pharmacokinetics and clinical response. Eur J Clin Pharmacol 42:85-88, 1992.
 
34) 古明地智, 北村磨知子, 柏崎禎夫:全身性エリテマトーデスの再燃に関する臨床的ならびに免疫学的研究. 日内会誌71:448-457, 1982.
 
35) Boumpas DT, Austin HA 3rd, Vaughn EM, et al:Controlled trial of pulse methylprednisolone versus two regiments of pulse cyclophosphamide in severe lupus nephritis. Lancet 340:741-745, 1992.
 
36) Felson DT, Anderson J:Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med 311:1528-1533, 1984.
PubMed
37) Carneiro JR, Sato EI:Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erytehmatosus. J Rheumatol 26:1275-1279, 1999.
 
38) Sato EI:Methotrexate therapy in systemic lupus erythematosus. Lupus 10:162-164, 2001.
PubMed
39) Kipen Y, Littlejohn GO, Morand EF:Methotrexate use in systemic lupus erythematosus. Lupus 6:385-389, 1997.
PubMed
40) Gansauge S, Breitbart A, Rinaldi N, et al:Methotrexate in patients With moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 56:382-385, 1997.
PubMed
41) Rahman P, Humphrey-Murto S, Gladman DD, et al:Effcacy and tolerability of methotrexate in antimalarial resistant lupus arthritis. J Rheumatol 25:243-246, 1998.
 
42) Rothenberg RI, Graziano FM, Grandone JT, et al:The use of methotrexate in steroidresistant systemic lupus erythematosus. Arthritis Rheum 31:612-615, 1988.
 
43) Boehm IB, Boehm GA, Bauer R:Management of cutaneous lupus erythematosus with low-dose methotrexate; indication for modulation of inflammatory mechanisms. Rheumatol Int 18:59-62, 1998.
PubMed
44) Abud-Mendoza C, Sturbaum AK, Vazquez-Compean R, et al:Methotrexate therapy in childhood systemic lupus erythematosus. J Rheumatol 20:731-733, 1993.
PubMed
45) Wilson K, Abeles M:A 2year, open ended trial of methotrexate in systemic lupus erythematosus. J Rheumatol 21:1674-1677, 1994.
 
46) Wallace CA:The use of methotrexate in childhood rheumatic diseases. Arthritis Rheum 41:381-391, 1998.
PubMed
47) Carneiro JR, Sato EI:Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. J Rheumatol 26:1275-1279, 1999.
PubMed
48) Ravelli A, Ballardini G, Viola S, et al:Methotrexate therapy in refractory pediatric onset systemic lupus erythematosus. J Rheumatol 25:572-575, 1998.
PubMed
49) Caccavo D, Lagana B, Mitterhofer AP, et al:Long-term treatment of systemic lupus erytehmatosus with cyclosporin A. Arthritis Rheum 40:27-35, 1997.
 
50) Dostal C, Tesar V, Rychlic I, et al:Effect of 1 year cyclosporine A treatment ontheactivity and renal involvement of systemic lupus erythematosus a pilot study. Lupus 7:29-36, 1998.
PubMed
51) Tam LS, Li EK, Leung CB, et al:Long-term treatment of lupus nephritis with cyclosporin A. QJ Med 91:573-580, 1998.
 
52) Morton SJ, Powell RI:An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes limitations of its use. Ann Rheum Dis 59:487-489, 2000.
 
53) Griffiths B, Emery P:The treatment of lupus with cyclosporin A. Lupus 10:165-170, 2001.
PubMed
54) Llorente L, Richaud-Patin Y, Fior R, et al:In vivo production of interleukin-10 by non-T cells in rheumatoid arthritis, Sjogren's syndrome, and systemic lupus erythematosus; a potential mechanism of B lymphocyte hyperactivity and autoimmunity. Arthritis Rheum 37:1647-1655, 1994.
PubMed
55) Hagiwara E, Gourley MF, Lee S, et al:Disease severty in patients with systemic lupus erythematosus correlates with an increased ratio of interleukin-10 interferon-y-secreting cells in the peripheral blood. Arthritis Rheum 39:379-385, 1996.
 
56) Houssiau FA Lefebvre C, Vanden Berghe M, et al:Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4:393-395, 1995.
PubMed
57) Park YB, Lee SK, Kim DS, et al:Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 16:283-288, 1998.
PubMed
58) Ishida H, Muchamuel T, Sakaguchi S, et al:Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/WFI mice. J Exp Med 179:305-310, 1994.
 
59) Llorente L, Richaud-Patin Y, Garcia-Padilla C, et al:Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 43:1790-1780, 2000.
PubMed
60) Tyndall A, Passweg J, Gratwohy A, et al:Haemopoietic stem cell transplantation in the treatment of severe autoimmune diseases 2000. Ann Rheum Dis 60:702-707, 2001.
PubMed
61) Traynor AE, Schroeder J, Rosa RM, et al:Treatment of severe systemic lupus erytematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation; a phase I study. Lancet 356:701-707, 2000.
 
62) Fouillard L, Gorin NC, Laporte JP, et al:Control of severe systemic lupus erythematosus after high-dose immunosuppressive therapy and transplantation of CD34+purified autologous stem cells from peripheral blood. Lupus 8:320-323, 1999.
PubMed
63) Brodsky RA, Petri M, Jones RJ:Haemopoietic stem cell transplantation for systemic lupus erythematosus. Rheum Dis Clin North Am 26:377-387, 2000.
PubMed
64) Burt RK, Marmont A, Schroeder J, et al:Intense immune suppression for systemic lupus-the role of hhaemopoietic stem cells. J Clin Immunol 20:31-37, 2000.
PubMed
65) Musso M, Porretto F, Crescimanno A, et al:Intense immunosuppressive therapy followed by autologous peripheral bood selected progenitor cell reinfusion for severe atltoimmune disease. Am J Hematol 66:75-79, 2001.
 
P.194 掲載の参考文献
1) 小松原良雄:抗関節症薬. リウマチ病セミナーV (七川歡次監修), pp277-285, 大阪, 永井書店, 1994.
 
2) Parelka K, Gatterova J, Gollerova V, et al:A 5-year randomized controlled, double-blind study of glycosaminoglycan polysulphuric acid complex (Rumalon) as a stracture modifying therapy in osteoarthritis of the and knee. Osteoarthritis Cartilage 8:335-342, 2000.
 
3) Raatikainen T, Vaananen K Tamolander G:Effect of glycosaminoglycan polysulfate on chondromalacia patellae. A placbo-controlled 1-year study:Acta Orthop Scand 61:443-448, 1990.
 
4) 井上康二:OAとサイトカイン, リウマチ病セミナーVIII (七川歡次監修), pp174-180, 大阪, 永井書店, 1997.
 
5) Dougados M, Nguyen M, Berdah L, et al:Effects of diacerin on the radiological progression of hip osteoarthritis:a three-year placebo-cntrolled study. Arthritis Rheum 43 supple 9:336, 2000.
 
6) ACR subcommittiee on osteoarhritis guideline special anicle:recommendations for the medical management of osteoarthritis of the hip and knee 2000 update. Arthritis rheum 43:1905-1915, 2000.
 
7) Deal CL, Moskowitz RW:Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chodroitin sulfate, and collagen hydrolysate Rheum Dis Clin Noth American 25:379-395, 1999.
 
8) Hoffer IJ, Kaplan LN, Hamadeh MJ, et al:Sulfate could mediate the thrapeutic effects of glucosamine sulfate. Metabolism 50:757-770, 2001.
 
9) 広田茂永:薬剤評価のためのOAのX線計測, リウマチ病セミナーVIII (七川歡次監修), pp 131-141, 大阪, 永井書店, 1997.
 
10) Hughes RA Carr AJ:A randomized double blind, placebo contoroled trial of Glucosamine to pain in osteoarthritis of knee. Arthritis Rheuma 43 supple 9:384, 2000.
 
11) Pavelka K, Gatterova J, Olejarova M, et al:Glucosamine sulfste decreases progression of knee osteoarthritis in a long-term, randomized, placebo-controlled, independent, confirmatory. Arthritis Rheum 43 supple 9:384, 2000.
 
12) Reginster JY, Derisy R, Rovati LC, et al:Long-term effecys of glucosamine sulfate on osteoarthritis progression. A randomizal, placebo-controlled clinical trial. Lancet 357:251-256, 2001.
 
13) Buckwater JA, Stanish WD, Rosier RN, et al:The increasing need for non operative treatment of patients with Osteoarthritis. Clin Orthop 385:36-45, 2001.
 
14) Das A, Hammad TA:Ethcacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese. Ascorbate in the management of knee osteoarthritis. Osteoarthritis-Cartilage 8:343-350, 2000.
PubMed
15) Leffer CT, Phillipp AF, Leffer SG, et al:Glucosamine, chondroitin, and manganese ascorbate for degenerative joint. Disease of the knee or low back:a randomized, double-blind, placebo-controlled Pilot study. Military Medicine 164:85-91, 1999.
 
16) McAlindon TE, Lavalley MP, Gulin JP, et al:Glucosamine and chondroitin for treatment of osteoarthritis. A systematic quality assessment and meta-analysis. JAMA 283:1469-1475, 2000.
PubMed
17) Leeb BF, Schwertzer H, Montag K et al:A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumat 27:205-211, 2000.
 
18) 山本鉄也, 脇谷滋之:関節軟骨変性の予防, リウマチ病セミナーXII (七川歡次監修), pp93-96, 大阪, 永井書店, 2001.
 
19) 牛山敏夫:膝関節症の関節内注射療法, リウマチ病セミナーXII (七川歡次監修), pp211-219, 大阪, 永井書店, 2001.
 
20) 戸田佳孝:グルコサミン製剤は高価であるが経口投与後消化されてしまう単なるアミノ酸に過ぎない. 日本リウマチ関節外科学会雑誌 20suppl:60, 2001.
 
21) Nakamura H, Tanaka M, Masuko-Hongo K, et al:Clinical effects and possible mechanisms of glucosamine in the treatment of osteoarthritis. Arthritis Rheum 44 suppl 9:309, 2001.
 
22) Buckwater JA, Callagham JJ, Rosier RN:From oranges and lemons to glucosamine and chondroitin sulfate:Clinical observations stimulate basic research. JBJS org 83-A:12661268, 2001.
 
23) Clark AG, Jordan JM, Vilim V, et al:Serum canilage oligomeric matrix protein reflex osteoarthritis presence and sensitivity. Arthritis Rheum 42:23562364, 1999.
 
24) Conrozier T, Saxne T, Shan Sei Fan C, et al:Serum concentration of cartilage oligomeric matrix protein and Bone sialoprotein in hip osteoarthritis:aone year prospective study. Ann Rheum Dis 57:527-532, 1998.
 

手術

P.201 掲載の参考文献
1) 三笠元彦:五十肩の歴史. 整災外37:1527-1532, 1994.
 
2) 神中正一:背痛と肩痛に関する臨床-夕話. 九大医報11:1-7, 1937.
 
3) Zuckermann JD:Frozen shoulder. The shoulder; a balance of mobility and stability (Eds, Matsen FA III, et al), pp253-268, American Academy of Orthopaedic Surgery, 1993.
 
4) Duplay ES:De la periarthrite scapulohumerale et des raideurs del'egnale quien son la consequence. Arch Gen Med 20:513-542, 1872.
 
5) Codman EA:Tendinitis of the short rotators. The shoulder, Thomas Todd, pp216-224, 1934.
 
6) 原 文吉:肩甲関節周囲組織の年齢的変化に就いて所謂五十肩の病理に関する研究. 日整会誌16:833-876, 1941.
 
7) DePalma AF:Frozen shoulder; adhesive capsulitis. Surgery of the shoulder, 3rd eds, pp138-176, Lippincott, 1950.
 
8) Meyer AW:Unrecognized occupation of the tendon of the long head of the biceps brachii. Arch Surg 2:130 144, 1921.
 
9) Pasteur F:Les algies del'epaule et la physiotherapie; la tenobtlrsite bicipitale. J Rasiol Electol 16:416-429, 1932.
 
10) Schrager VL:Tenosynovitis of the long head of the biceps humeri. Surg Gynecol Obstet 66:785-790, 1938.
 
11) Lippman RK:Frozen shoulder, periarthritis. Bicipital tenosynovitis. Arch Surg 47:283-296, 1943.
 
12) Hitchcock HH:Painful shoulder; observations on the role of the tendon of the long head of the biceps brachii in its causation. J Bone Joint Surg 30A:263-273, 1948.
 
13) 安達長夫:五十肩の病態について. 整災外30:3-9, 1987.
 
14) Lundberg BJ:The frozen shoulder; clinical and radiographic obserbations. The effect of manipulation under general anesthesia. Structure and glycosaminoglycan content of the joint capsule. Local bone metabolism. Acta Orthop Scand 119:1-59, 1969.
 
15) Riedel R:Die Versteifung des Schultergelenks durch Haengelassen des Armes. Muench Med Wsshr 63:13-97, 1916.
 
16) Neviaser JS:Adhesive capsulitis of the shoulder. J Bone Joint Surg 27:211-222, 1945.
 
17) Nicholson GG:The effects of passive joint mobilization on pain and hypomobility associated with adhesive capsulitis of the shoulder. Orthop Sports Pyhs Ther 6:238-246, 1985.
 
18) 信原克哉:肩-その機能と臨床 (第2版), pp 136-149, 東京, 医学書院, 1987.
 
19) Nobuhara K, Sugiyama D, Ikeda H, et al:Contracture of the shoulder. Clin Orthop 254:105-110, 1990.
PubMed
20) Ozaki J, Nakagawa Y, Sakurai G, et al:Recalcitrant chronic adhesive capsulitis of the shoulder. Role of contracture of the coracohumeral ligament and rotator interval in pathogenesis and treatment. J Bone Joint Surg 71-A:1511-1515, 1989.
PubMed
21) Neer CS, Satterlee CC, Dalsey RM, et al:The anatomy and potential effects of contracture of the coracohumeral ligament. Clin Orthop 280:182-185, 1992.
PubMed
22) 三木威勇治:五十肩. 日本医書出版, 1947.
 
23) 渡辺正毅:五十肩. 外科23:1561-1568, 1961.
 
24) 山本龍二:五十肩の病因論. 整災外37:1533-1545, 1994.
 
25) Simmonds FA:Shoulder pain; with particular reference to the frozen shoulder. J Bone Joint Surg 31-B:426 432, 1949.
 
26) Macnab I:Rotator cuff tendinitis. Ann R Coll Surg Engl 53:271-283, 1973.
PubMed
27) DePalma AF:Loss of scapulohumeral motion (frozen shoulder). Ann Surg 135:193-197, 1952.
 
28) Bruckner FE, Nye CJ:A prospective study of adhesive capsulitis of the shoulder (frozen shoulder). in a high risk population. Q J Med 50 (195):191-204, 1981.
 
29) Travell JG:Myofascial pain and dysfunction. Trigger point manual, pp410-424, Williams & Wilkins, 1983.
 
30) Cailliet R:Shoulder pain, 2nd ed, Philadelphia, FA Daris Co, 1981.
 
31) Tyber MA:Treatment of the painful shoulder syndrome with amitriptyline and lithium carbonate. Can Med Assoc J 111:137-140, 1974.
PubMed
32) Wright V, Hag AM:periarthritis of the shoulder. Aetiological consideratio With particular reference to personality factors. Ann Rheum Dis 35:213, 1976.
 
33) Bowman CA, Jeffcoate WJ, Pattrick M, et al:Bilateral adhesive capsulitis, oligoarthritis and proximal myopathy as presentation of hypothyroidism. Br J Rheumatol 27:62-64, 1988.
PubMed
34) Wohlgethan JR:Frozen shoulder in hyperthyroidism. Arthritis Rheum 30:936939, 1987.
 
35) Riley D, Lang AE, Blair RD, et al:Frozen shoulder and other shoulder disturbances in Parkinsonls disease. J Neurol Neurosurg Psychiatry 52:63-66, 1989.
 
36) Bridgman JF:Periarthritis of the shoulder and diabetes mellitus. Ann Rheum Dis 31:69-71, 1972.
PubMed
37) Kay NR:Fibromatosis and diabetes mellitus. Lancet 8:303, 1981.
 
38) Pal B, Anderson J, Dick WC:Limitations ofjoint mobility and shoulder capsulitis in insulin and non-insulin dependent diabetes mellitus. Br J Rheumatol 25:147-151, 1985.
 
39) Bulgen DY:Immunological studies in the frozen shoulder. J Rheumatol 9:893-898, 1982.
PubMed
40) Bulgen DY, Hazleman BL, Voak D:HLA-B27 and frozen shoulder. Lancet 15:1042-104, 1976.
 
41) Young A:Immunological studies in the frozen shoulder. Shoulder Surgery, pp110-113, Springer-Varlag, 1982.
 
42) Rodeo SA, Hannafin JA Tom J, et al:Immunolocalization of cytokines and their receptors in adhesive capsulitis of the shoulder. J Orthop Res 15:427-436, 1997.
PubMed
43) Hannafin JA:Adhesive capsulitis; capsular fibroplasia of the glenohumeral joint. J Shoulder Elbow Surg 3:5, 1994.
 
44) Hannafin JA, Chiaia TA:Adhesive capsulitis. A treatment approach. Clin Orthop 372:95-109, 2000.
PubMed
45) Rizk TE, Pinals RS:Histocompatibility type and racial incidence in frozen shoulder. Arch Phys Med Rehabil 65:33-34, 1984.
PubMed
46) Bunker TD:The pathology of frozen shoulder; Dupuytren-like disease. J Bone Joint Surg 77B:677-683, 1992.
 
47) Bunker TD, Reilly J, Baird KS, et al:Expression of growth factors, cytokines and matrix metalloproteinases in frozen shoulder. J Bone Joint Surg Br 82:768-773, 2000.
PubMed
48) Hutchinson JW, Tiemey GM, Parsons SL, et al:Dupuytrenis disease and frozen shoulder induced by treatment with a matrix metalloproteinase inhibitor. J Bone Joint Surg 80-B:907-908, 1998.
 
49) Kopell HP:Pain and frozen shoulder. Surg Gynecol Obstet 109:92-93, 1959.
PubMed
50) Hollander JIJ:Intra-arthicular hyprocortisone in arthritis and allied condition. J Bone Joint Surg 35-A:983-990, 1953.
 
51) Cyriax J, et al:Hydrocortisone and soft tissue lesions. Br med 2:966-968, 1953.
PubMed
52) Leardini G, et al:Intra-anicular infections of hyaluronic acid in the treatment of painful shoulder. Clin Ther 10:521-526, 1988.
 
53) 米田 稔, 岡村健司, 林田賢治:有痛性肩関節疾患に対する高分子量ピアルロン酸ナトリウム (アルツ) 療法の検討. 臨床リウマチ10:63-66, 1998.
 
54) Nobuhara K, Supapo眠Hino T:Effects ofjoint distension in shoulder diseases. Clin Orthop 304:25-29, 1994.
 
55) 米田 稔:肩関節の鏡視下手術. 現状と展望. 日整会誌72:85-101, 1998.
 
56) Bennett WF:Addressing glenohumeral stifiiriess while treating the painful and stiff shoulder arthroscopically. Arthroscopy 16:142-150, 2000.
PubMed
57) 武富由雄:肩疾患保存療法 (信原克哉編), pp70-75, 東京, 金原出版, 1997.
 
58) Griggs SM, Ahn A, Green A:Idiopathic adhesive capsulitis:a prospective functional outcome study of nonoperative treatment. J Bone and Joint Surg 82-A:1398-1407, 2000.
PubMed
59) Taketomi Y, Muraki T:Rehabilitation of the shoulder-effect of hold-relax technique on stiff and painful shoulder. Shoulder Surgery Asian Perspectove 2:216-218, 1997.
 
60) Warner JJP, Allen A, Marks PH, et al:Arthroscopic release for chronic, refractory adhesive capsulitis of the shoulder. J Bone and Joint Surg 78. A:1808-1816, 1996.
 
61) Pearsall IV AW, Osbahr DC, Speer KP:An arthroscopic technique for treating patients with frozen shoulder. Arthroscopy 15:2-11, 1999.
 
62) Klinger H-M, Otte S, Lorenz F, et al:Early arthroscopic release of the resistant frozen shoulder (10th Congress of ESSKA), pp220, Rome, 2002.
 
P.207 掲載の参考文献
1) 出沢 明, 三木 浩, 山根友二郎:脊椎疾患に対するvideo-assisted laparoscopic and thracoscopic surgery. 別冊整形外科30:219-225, 1996.
 
2) 遠藤健司, 武田祐介, Mamay THら:成人側彎症に対し胸腔鏡と腹腔鏡を併用した前方解離術の経験. 臨整外35:53-58, 2000.
 
3) Marnay TH:Chirurgie video-assistee miniinvasive du rachis par voie anterieure. Cahiers d'ensegnement de la SOFCOT 1999, pp161-184, 1999.
 
4) 矢吹省司, 菊池臣一, 紺野慎一ら:胸腰椎破裂骨折に対する鏡視下手術. 脊椎脊髄11:29-33, 1988.
 
5) 遠藤健司, 武田祐介, Constantin Dら:内視鏡を使用した第1,第2腰椎圧迫骨折に対する横隔膜下アプローチの検討.脊椎脊髄神経手術手技3:116-119, 2001.
 
P.215 掲載の参考文献
1) 高倉義典ら:人工足関節について. 臨床整形外科12:177-184, 1977.
 
2) Takakura Y, et al:Ankle arthroplasty; A comparative study of cemented and uncemented ceramic prostheses. Clin Orthop 252:209-216, 1990.
PubMed
3) 高倉義典:OS NOW. 足関節全置換術5:140-151, 1992.
 
4) 高倉義典:NEW MOOK慢性関節リウマチ. 足の手術的治療1:248-256, 1997.
 

書評

最近チェックした商品履歴

Loading...